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ABSTRACT 
 
 
 
Cissell, Kyle A. Ph.D., Purdue, December, 2010. Luminescence-Based MicroRNA 
Detection Methods. Major Professor: Sapna K. Deo. 
 
 
 
MicroRNAs (miRNA) are short, 18-24 nucleotide long noncoding RNAs. These 
small RNAs, which are initially transcribed in the nucleus, are transported into the cell 
cytoplasm where they regulate protein translation either through direct cleavage of 
mRNA, or indirect inhibition through binding to mRNA and disrupting the protein 
translation machinery. Recently, miRNAs have gained much attention due to their 
implication in numerous diseases and cancers. It has been found that heightened or 
lowered levels of miRNA in diseased cells vs. healthy cells are linked to disease 
progression. It is therefore immensely important to be able to detect these small 
molecules. Current detection methods of Northern blotting, microarrays, and qRT-PCR 
suffer from drawbacks including low sensitivity, a lack of simplicity, being semi-
quantitative in nature, time-consuming, and requiring expensive instruments. This work 
aims to develop novel miRNA technologies which will address these above problems. 
Bioluminescent labels are promising alternatives to current methods of miRNA detection. 
Bioluminescent labels are relatively small, similar in size to fluorescent proteins, and they 
emit very intense signals upon binding to their substrate. Bioluminescent labels are 
advantageous to fluorescent labels in that they do not require an external excitation 
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source, rather, the excitation energy is supplied through a biochemical reaction. 
Therefore, background signal due to excitation is eliminated. They also have the 
advantage of being produced in large amounts through bacterial expression.  
Four miRNA detection methods are presented which utilize luminescence-based 
methods. Three employ Renilla luciferase, a bioluminescent protein, and one is based on 
fluorescence. The presented methods are capable of detecting miRNA from the picomole 
(nanomolar) level down to the femtomole (picomolar) level. These methods are rapid, 
sensitive, simple, and quantitative, can be employed in complex matrices, and do not 
require expensive instruments. All methods are hybridization-based and do not require 
amplification steps.  
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CHAPTER 1: MICRORNA INTRODUCTION 
 
1.1 Opening Remarks 
Few discoveries have had such a large impact on all of science as microRNA has. 
MicroRNAs (miRNA) are 18-24 nucleotide non-coding RNA molecules involved in 
RNA interference which regulates protein translation. Within the past few years, miRNA 
research programs have flourished because of results that were discovered in the 
laboratory of Dr. V. Ambros at Dartmouth Medical School, where the developmental 
gene pathway of soil nematode C. elegans was being studied. While performing these 
studies, the researchers discovered that the gene lin-14 was negatively regulated by the 
gene lin-4, which encoded two small non-coding strands of RNA, one 22 nucleotides and 
the other, 61 nucleotides 1. Both lin-14 and lin-4 control larval development, and have 
recently been shown to regulate the life-span of C. elegans 2. The 61 nucleotide strand 
was predicted to fold into a stem-loop structure believed to be the precursor of the 
smaller 22 nucleotide strand. This discovery at the time was viewed as an anomaly, 
unlikely to occur frequently in nature. Less than a decade later, however, another non-
coding small RNA molecule was discovered, again in the developmental studies of C. 
elegans 3. Here, Ruvkun and colleagues discovered that this small, noncoding RNA 
molecule encoded by the gene let-7 regulated the transcription of lin-14. The discovery of 
the regulatory gene let-7 sparked the recent boom in miRNA research. Soon after the 
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discovery of let-7, over one hundred new genes for noncoding small RNAs (miRNAs) 
were discovered in humans, worms, and Drosophila 4-6.  
Gene regulation by miRNAs plays a role in cell proliferation, cell death, and 
tumorigenesis, as well as mammalian cell development 7, 8. There are thousands of 
published miRNA sequences located on miRBase 9, 10, a database for miRNAs. Many of 
these miRNA sequences overlap from species to species; however, there are numerous 
unique sequences accounted for in nature. The importance of miRNA and its role in gene 
interference cannot be stressed enough, especially since the 2006 Nobel Prize in 
Medicine was awarded to Andrew Fire and Craig Mello for their work in RNA 
interference, in which miRNA plays a vital role. MicroRNA raises questions as to the 
actual function of genes, in particular, the purpose of noncoding strands of RNA encoded 
from genes. It has long been thought that most RNA code for the translation of proteins. 
Could it be possible that there is more to RNA than previously speculated? In fact, a 
significant amount of RNA in a cell does not code for the translation of protein, rather it 
regulates gene expression. For example, it has been found that of the 62% of the mouse 
genome that is transcribed, approximately one-half of the RNA is noncoded 11, 12.  
 
1.2 miRNA Biogenesis 
MiRNA biogenesis originates in the nucleus and eventually results in mature 
miRNA in the cytoplasm (Figure 1.1). Before mature miRNA is formed, primary miRNA 
(pri-miRNA), a long strand of RNA containing stem-loop structures (up to 1kb in length), 
is initially transcribed by RNA polymerase II 13, and further excised by the endonuclease 
Drosha 14. After excision, the former pri-miRNA, termed pre-miRNA, is exported to the 
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cytoplasm by the RNA-binding protein Ran-GTP and the exporter receptor Exportin-5 15-
18
. This pre-miRNA consists of a long stem of approximately 25-30 bp along with a small 
loop structure. After the pre-miRNA is released from the Exp-5, it is cleaved by an 
RNase III enzyme known as Dicer, to generate mature miRNA. The mature miRNA is 
further incorporated with the RNA-induced silencing complex (RISC), consisting of 
proteins from the argonaute family 19, by which the miRNA anneals to the 3’ untranslated 
region of its complementary target messenger RNA (mRNA) 20, 21. Once bound to the 
target mRNA, the miRNA can induce cleavage of the mRNA, regulating protein 
translation directly, or regulating translation indirectly through remaining bound to the 
mRNA. Due to the similarities between siRNA, miRNA and piwiRNA, it is important to 
differentiate between each of these small RNAs. While all three are nearly the same 
length, they are processed differently in the cell. All three are generated by RNase 
enzymes Dicer and Drosha. The cleavage of exogenous long dsDNA precursors in 
response to viral infections or artificial introduction generates small interfering RNAs 
(siRNAs), whereas the processing of genome-encoded stem-loop structures generates 
miRNAs. A recently uncovered class of small RNAs called PIWI-interacting RNAs 
(piRNAs) are slightly longer than miRNAs (~26-31 nt) 22. The proteins required for this 
pathway are unknown but it is known that the piRNAs function to silence transposons 
through a complex amplification process that can even modify histones and carry out 
DNA methylation 23. Recently, siRNA has found much utility in therapeutics. There have 
been numerous examples in medical literature in which siRNAs are delivered to diseased 
cells. Due to the high RNAse activity in serum, great care must be used to avoid siRNA 
degradation prior to delivery. 
Figure 1.1 miRNA biogenesis. miRNA is initially encoded in genomic DNA. It undergoes 
transcription, followed by a series of processing steps to produce mature miRNA, which binds to 
mRNA, inhibiting protein translation
2007 American Chemical Society.
 
 
Numerous delivery methods have been employed, including liposomal
nanoparticle 25, carbon nanotube
organs. These delivered siRNAs accomplish the task of regulating protein translation 
through binding to key genes. While siRNA delivery is beyond the scope of this thesis, it 
is worth introducing due to its important role in therapeutics. 
 
MicroRNA has been implicated in multiple diseases, including cancer. It can be 
found freely circulating in bodily fluids such as serum
. Reprinted with permission from Reference 5
 
 
26
, viral delivery 27, as well as direct injection to target 
 
1.3 miRNA Implications in Disease 
 
28
, urine 29, sputum
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24
, 
 
30
 and saliva 31. 
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The utility of circulating miRNA as cancer biomarkers, therefore would be highly 
advantageous in terms of developing rapid diagnostic tools. Although nascent RNA is 
unstable in serum due to the very high RNAse activity, miRNA displays remarkable 
stability, suggesting that miRNA is somehow protected. It has been hypothesized that 
serum RNA is protected via protein or liposomal encapsulation 32. It is possible that 
miRNA is protected in this manner as well. Most likely, miRNA does not freely circulate 
in serum as naked single-stranded small length RNA.  
As the study of miRNA increases, more and more researchers are finding links 
between miRNA expression levels (the amount of miRNA in the cells), and the onset of 
cancer and other diseases 33. Numerous studies have found that miRNA expression levels 
are increased (upregulated) or decreased (downregulated) in cancer cells. For example, 
miR-15a and miR-16-1 are downregulated in B-cell chronic lymphocytic leukemia 34; 
miR-143 and miR-145 are downregulated in breast, prostate, cervical, and lymphoid 
cancer cells 35; while miR-21, miR-373, and miR-520c are upregulated in breast cancer 
cells 36, 37 and miR-184 is upregulated in prostate cancer cells 38. There are certainly 
hundreds more miRNAs which are linked to cancer and the list grows larger as more and 
more studies are performed.  Along with cancer, miRNAs have been shown to play an 
important role in cardiovascular disease. Hammond and colleagues have found that in the 
presence of mutated Dicer, the enzyme which cuts pre-miRNA into mature miRNA, the 
miRNA which is necessary for cardiovascular health cannot be processed. This ultimately 
results in progressive dilated cardiomyopathy, which leads to heart failure, and eventually 
death 39. Due to the significance of miRNA in disease, it is necessary to develop miRNA-
based therapeutic methods. Overall, miRNAs are related to several diseases including 
6 
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neurological 40, cardiovascular 41, cancer, and immunological 42. Due to their widespread 
gene regulation and their affects on human health, miRNAs have garnered much attention 
in the biomedical field.  
 
1.4 miRNAs and Their Applications in Therapeutics 
Due to the increasing correlation of miRNA levels with diseases, it is necessary to 
explore various therapeutic options for miRNA function inhibition or delivery of miRNA 
in cells where the onset of disease may occur if miRNA level(s) are downregulated. In 
order to accomplish these tasks, miRNAs must be comparatively studied in both healthy 
and unhealthy cells.  Once a miRNA has been determined to be a viable biomarker, it will 
be necessary to explore options on how to counteract the disease linked to the specific 
miRNA or miRNAs. If the miRNA levels are too high, a few options to tackle this 
problem may be used. Anti-sense oligonucleotides which hybridize with the miRNA can 
be introduced, preventing the target miRNA from hybridizing with the 3’ UTR of the 
mRNA.  By doing this, it is conceivable that aberrant gene regulation will not occur from 
the target miRNA. A more efficient method to design antisense miRNA is to employ 
locked nucleic acid (LNA) probes instead of DNA oligonucleotide probes. LNAs contain 
a 2’-O-4’C methylene bridge on the furanose ring which results in a more rigid double-
stranded nucleic acid structure that is more thermally stable as well. This could prevent 
the dissociation of the hybrid between target miRNA and antisense miRNA. Also, it has 
been found that antagomirs, anti-sense oligonucleotides which were conjugated to 
cholesterol to aid in cellular delivery, may be beneficial therapeutic agents for tumors or 
other diseased cells. In a study by Krutzfeldt and colleagues, it was determined that 
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cholesterol-modified antagomirs injected into mice inhibit miRNA activity 43. For over-
expressed miRNAs which lead to tumor growth, the delivery of antagomirs or antisense 
LNA probes, coupled with delivery of miRNAs which lead to tumor suppression are 
ideal. Lentivirally expressed antagomirs have also been employed for repression of 
miR18a, miR19b, and miR20a 44. It is also possible to transfect cells with miRNA in 
order to inhibit protein translation, rather than to promote protein translation. For 
example, let-7 miRNA transfection has been shown to reduce tumor growth in cancer 
cells 45-47. Introduction of microRNA miR16 reduces tumor growth in prostate cancer 
cells 48. In order to deliver the therapeutic agents, non-invasive delivery is desired, such 
as liposomal delivery. Recently, single-walled carbon nanotube (SWNT) delivery based 
on endocytosis has shown promise as a drug delivery alternative 49. SWNTs have already 
been shown to deliver siRNA to cells 50, 51, and thus can be applied to miRNA delivery as 
well. Additionally, the toxicity of SWNT can be substantially decreased by using smaller-
length SWNTs which are expelled quickly after use in the urine 52. Before these 
therapeutic methods may be used on humans, much research needs to be performed 
regarding miRNA levels in healthy vs. unhealthy cells to assure that addition of 
antagomirs and/or miRNAs will not cause harm in the body by inhibiting or promoting 
expression of proteins which can result in the onset of a different type of disease. While 
therapeutics is a fascinating facet of miRNA research, they are not the focus of this work.  
 
1.5 Standard miRNA Detection Methods 
There are currently multiple miRNA detection methods presented in literature, 
most of which are based upon hybridization. Mostly all detection methods rely on an 
8 

optical label in order to translate the hybridization event into a measureable signal. There 
are, however, label-free methods such as those employing Raman spectroscopy. In one 
particular example, silver nanorods are immobilized on a substrate 53. The target nucleic 
acids are then adsorbed to the nanorods, resulting in a Raman signal that is sequence-
specific. Through measuring the peaks of known oligonucleotides, it is possible to 
discern the sequence of small RNAs present in a sample. Apart from the small number of 
label-free examples, most miRNA detection methods are based upon hybridization 54, 55, 
although this underlying method can be broken down into the following categories: 
Polymerase chain reaction (PCR)-based methods, blotting methods, microarray-based 
methods, flow cytometry, and emerging new analytical methods. No matter what the 
detection method, each assay must have a way to produce a signal upon hybridization; 
that is, a transducer must be present in order to translate the hybridization event into a 
measurable signal.   
PCR methods utilize the annealing and extension events of complementary primer 
oligonucleotides to detect miRNA through amplification of miRNA present in the 
sample. In miRNA profiling, quantitative reverse transcription PCR (qRT-PCR) is widely 
used due to its ability to quantitate miRNA copy numbers and its high specificity. In this 
method, reverse transcriptase converts RNA into DNA through the presence of an RT-
PCR miRNA-specific primer to form a cDNA library. This cDNA and forward and 
reverse PCR primers are employed to amplify the cDNA. Because of the small length of 
the miRNA oligonucleotides, the primer oligonucleotide must also be short in length.  
This small length primer, with a low melting temperature, can have adverse effects on the 
efficiency of the polymerase chain reaction. This problem can be combated by detecting 
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miRNA precursors rather than mature miRNA 56; however, pre-miRNA may not be 
homologous with the mature miRNA levels in the cell. Therefore, primer design and 
small RNA extraction is critical in order to not amplify non-specific regions of RNA.      
There are several commercially available kits which employ RT-PCR to detect 
miRNA. Among them are the miR-Vana kit available from Ambion 57 and the miRCURY 
LNA PCR kit from Exiqon, both of which employ SYBR green; and the TaqMan probe 
assay from Applied Biosystems. In the miRCURY kit, cDNA is created through reverse 
transcription, followed by PCR amplification. During each amplification, SYBR green, a 
fluorescent dye which has an affinity for the minor groove of dsDNA, becomes highly 
fluorescent upon binding to dsDNA. This increase in fluorescence can be quantified and 
the actual amount of miRNA correlated. In the case of the TaqMan probe, upon cDNA 
formation, PCR primers are added, along with a hairpin probe containing a fluorophore 
and quencher which binds to a region downstream of the primer extension. The 
polymerase, upon contacting the hairpin probe, cleaves the fluorophore, resulting in an 
increase in fluorescence. The resulting fluorescence intensity can be employed to 
determine the initial miRNA concentration. 
Another widely used miRNA detection method is Northern blotting 3, 5, 34, 58. In 
Northern blotting, a complementary labeled oligonucleotide probe binds to a target 
miRNA captured on a nitrocellulose membrane. This method is time-consuming, often 
taking days for completion; however, it is considered the gold standard for miRNA 
detection and validation. A complication is that blotting methods are not sensitive and 
thus require large amounts of sample (~10-30 µg) for miRNA detection and possess 
detection limits in the nanomolar range. This sensitivity problem has been minimized 
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with the addition of locked nucleic acids (LNAs) to the probe sequence, increasing the 
detection sensitivity 10-fold compared to normal RNA or DNA oligonucleotides 59. 
Although PCR and Northern blotting are important tools for miRNA detection, it is of 
interest to explore simpler, faster, and more sensitive detection methods.  
Microarray technology has become an important tool for scientists working on 
genome analysis. Microarrays are being utilized more and more by scientists seeking 
ways to decrease sample volume, test multiple samples simultaneously, and decrease 
assay time. The miRNA microarray chips can contain an array of immobilized 
oligonucleotide probes which are complementary to a cDNA sequence which is reverse 
transcribed from mature miRNA. These cDNA probes are labeled with a signal 
transducer, such as Cy 3, Cy 5, or biotin, to characterize the hybridization event. In some 
cases, the signal transducer may directly be conjugated to the miRNA present in the 
sample. The target is then added to each well, followed by wash steps to remove 
unhybridized molecules. Each well produces a particular color upon staining or yield 
fluorescence signals. The intensity of these colors or fluorescence is measured to 
determine the amount of hybridized miRNA in a sample well. Perhaps the greatest 
advantage of the microarray platform over other detection methods is its high-
throughput-screening capability. Due to this advantage, microarrays are widely utilized to 
characterize the expression profiles of miRNA 60-63. Although the cost of microarray 
technology is front-loaded with overhead from the robotics needed for fabrication, in the 
long run, microarrays are cost-effective in large laboratory settings where thousands of 
samples are screened daily. However, this is not suitable for small research laboratories. 
Microarrays have other drawbacks along with their high cost, including low sensitivity 
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due to minimal sample volume, and the possibility of cross-hybridization, which may 
occur when samples differ by only one base.     
There have been many cited articles utilizing microarrays in the detection and 
profiling of miRNA 61, 64-67. In one example, Croce and colleagues designed a microarray 
for profiling 245 miRNAs from humans, mice, and Arabidopsis 68. In this article, the 
authors genetically modified target miRNA by reacting it with biotin-containing primers.  
The biotin-containing target was allowed to hybridize with solid-phase oligonucleotides 
representing the 245 different miRNA sequences. After wash steps to remove unbound 
miRNA, the hybridized probes were reacted with streptavidin-Alexa 647 conjugate. The 
affinity of the biotin-streptavidin conjugate allows the Alexa 647 dye to serve as the 
signal transducer, detecting hybridization. Fluorescence measurements determined the 
intensity of each well in order to characterize the expression profile of the target miRNA. 
This method showed that only 2.5 µg of total RNA sample is needed to detect miRNA 
compared to ~10 µg for Northern blotting. Multiple other examples of miRNA profiling 
through microarrays exist in literature. Too many are present to reference here, although 
perhaps the greatest achievement of microarray profiling of miRNAs is the strong 
predictions which can be made concerning tumor formation. It has been found that in 
patient samples with certain types of tumors, expression profiles reveal numerous 
dysregulated miRNAs. For example, in patient serum with small cell lung carcinoma, the 
miRNAs miR233 and miR25 are significantly upregulated. In breast cancer patients, the 
microRNA miR21 is highly upregulated.  
Flow cytometry is also another method for miRNA analysis. In flow cytometry-
based methods, a sample is hydro-dynamically focused in a sheathing liquid to produce a 
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narrow stream which allows only one particle through the stream at a time. A laser is 
focused on this stream with detectors placed along the stream to detect any laser-induced 
fluorescence. Spikes in fluorescence are indications that the target fluorophore has passed 
through the flow cell. In terms of miRNA detection, complementary oligonucleotides 
capture amplified, labeled target, and depending on the fluorophores which are used to 
modify the targets, the amount of miRNA in a sample can be determined. Recently, a 
bead-based flow cytometry method has been performed to profile 217 miRNAs 69. More 
specifically, complementary oligonucleotide capture probes were coupled with 
polystyrene beads, which were made up of characteristic fluorescent molecules to 
produce spectrally distinct polystyrene beads. Each color corresponded to a specific 
miRNA. In order to determine miRNA abundance, miRNAs were PCR-amplified using a 
biotinylated primer, hybridized with the complementary oligonucleotide-labeled beads, 
and stained with streptavidin-phycoerythrin. Parallel experiments with a microarray 
format revealed that the bead-based flow cytometry method showed increased specificity 
for single nucleotide mismatches compared to the microarray.  
While the previously mentioned methods have been widely used, drawbacks exist 
for each method. Northern blotting is very time consuming and only qualitative. 
Microarrays, although capable of high-throughput screening, are very costly and suffer 
from difficulties with specificity. PCR-based methods require amplification of target, 
increasing the total number of steps involved in detection. Flow cytometry requires 
highly expensive equipment and amplification of target, increasing the total assay time. 
Therefore, methods for miRNA detection are needed which are rapid, do not require 
amplification of target, are highly sensitive and quantitative, do not require expensive 
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equipment, and are highly specific. New and emerging methods which address the 
previously stated drawbacks are described next.  
  
1.6 Overview of New and Emerging Methods of miRNA Detection 
Numerous methods have been developed which seek to overcome the drawbacks 
mentioned above associated with Northern blotting, microarrays, qRT-PCR, and flow 
cytometry. These new methods employ electrochemical, luminescence-based, and other 
optical methods of detection. Table 1.1 summarizes the methods of microRNA detection 
mentioned in this chapter. To overcome the low sensitivity of the above methods, labels 
such as quantum dots and gold nanoparticles have been evaluated by Ruan and 
colleagues 70. In this method, isolated miRNA is oxidized to convert the 3’ terminal 
hydroxyls on the ribose ring into a dialdehyde. The dialdehyde reacts with a biotin-X-
hydrazide via condensation to biotinylate the target miRNA (Figure 1.2A). The 
biotinylated sample miRNA is added to the immobilized capture probe. After a wash 
step, hybridization is detected using a streptavidin-quantum dot conjugate (Figure 1.2B). 
When the hybridized probes are excited with light, the quantum dots will fluoresce. This 
fluorescence, resulting from the hybridization, may be detected with a laser confocal 
scanner. This method produces a lower detection limit of approximately 0.4 fmoles, 
much lower than Northern blotting methods.  
 
 

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Table 1.1 Standard and emerging miRNA detection methods 
Method Assay Description 
Detection 
Limit 
Reference 
(s) 
Northern 
blotting 
Transfer of miRNA onto nitrocellulose membrane, 
followed by washing with labeled complementary probe 
~nM 3, 5, 34, 58 
qRT-PCR Reverse transcription of miRNA target, followed by real-
time PCR detected through fluorescence 
aM  57 
microarray 
Reverse transcription of miRNA target, followed by 
addition of modifying cDNA with label, which is 
hybridized to a solid-phase capture probe on a substrate 
pM  61, 64-67 
flow 
cytometry 
Fluorescent-labeled PCR-amplified miRNA target 
hybridize with probe conjugated to polystyrene beads. 
Hydrodynamically-focused sheathing liquid allows for in-
line flow of beads. Labeled target detected via fluorescence 
  69 
electro-
chemical 
miRNA target hybridizes with immobilized capture probe. 
miRNA target reacts with electrocatalytic nanoparticles 
which produce an electric current upon addition of an 
oxidizing agent 
80 fM 71 
luminescence  
Biotinylated miRNA target hybridizes with an immobilized 
capture probe. Streptavidin-modified quantum dots are 
added, and detected via fluorescence excitation 
39 pM 70 
 
miRNA target and fluorophore/quencher probe hybridize 
with different regions of a ribozyme, which results in 
cleavage of the fluorophore/quencher probe, generating 
fluorescence upon fluorophore excitation 
5 nM 73 
 
Two fluorophore-labeled probes hybridize adjacently with 
miRNA target and are detected via fluorescence correlation 
spectrocsopy 
 100 fM 74 
 
miRNA target hybridizes with a hairpin oligonucleotide 
tethered to a magnetic particle, opening up the hairpin. A 
CdSe-modified oligonucleotide hybridizes adjacently to the 
miRNA. Upon addition of silver ions, ligand exchange 
occurs, releasing Cadmium ions, which bind to a 
fluorogenic substrate, generating fluorescence 
35 fM 75 
 
RNA-primed array-based Klenow enzyme assay where 
miRNA target hybridizes with adjacent hairpin probes, 
releasing a DNA fragment through enzyme cleavage, which 
hybridizes with another pair of adjacent probes. Another 
enzyme cleavage reaction results in generation of 
fluorescence 
5 fM 77 
optical 
LNA-modified capture probes bybridize with miRNA, 
which is poly-adenylated. Gold Nanoparticle-polyT 
conjugates added and detected through surface plasmon 
resonance imaging 
50 fM 76 
Biotinylated miRNA target hybridizes with an immobilized 
capture probe. Streptavidin-modified colloidal gold is 
bound to miRNA, followed by silver enhancement. Visual 
detection performed via CCD camera. 
10 pM 70 
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As an alternate to quantum dot probes, gold nanoparticles conjugated to 
streptavidin were utilized (Figure 1.2B). Once the target miRNA is labeled with the 
nanoparticle-streptavidin complex, followed by hybridization with the complementary 
oligonucleotide probe, silver enhancement occurs, resulting in a change in color on the 
gold nanoparticle. During silver enhancement, colloidal gold, in the presence of a 
reducing agent and silver ions, catalyzes the reduction of silver ions to metallic silver, 
which forms on the surface of the gold nanoparticle. This buildup of metallic silver 

Figure 1.2 Solid-phase quantum dot/ gold nanoparticle miRNA detection. A) Direct labeling of 
miRNA. B) Fluorescence-based miRNA detection through streptavidin-labeled quantum dots and 
miRNA detection through silver enhancement on streptavidin-labeled gold nanoparticles. 
Reprinted with permission from Reference 54. Copyright 2007 American Chemical Society. 
 
 
changes the color of the nanoparticle which may be detected via a CCD camera mounted 
to a microscope. This colorimetric method of miRNA detection was found to have a 
lower detection limit of only 0.1fmol. The quantum dot and gold nanoparticle-based 
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hybridization methods are both highly sensitive and prove to be viable alternatives to the 
time-consuming Northern blotting method.  
Recently, a novel electrochemical-based solid phase method of miRNA detection 
was introduced by Gao and Yang utilizing electrocatalytic OsO2 nanoparticle tags which 
produces a detection limit in the femtomolar range 71 (Figure 1.3). In this method, 
complementary oligonucleotide capture probes are immobilized on an ITO-coated glass 
slide, followed by washing with periodate-treated target miRNA, allowing for 
hybridization to take place. Upon hybridization, the OsO2 nanoparticles were added to the 
reaction chamber. A condensation reaction occurs between the isoniazid and 3’ terminal 
dialdehydes of the miRNA molecules.  Once the capped nanoparticles are fused to the 
miRNA, the hybridization event can be characterized via the electrochemical current 

Figure 1.3 Electrocatalytic miRNA detection. Isoniazid-labeled miRNAs are hybridized with 
tethered capture oligonucleotide probes. Following addition of hydrazine, an increase in current is 
observed, allowing for quantitation of miRNA. Reprinted with permission from Reference 54. 
Copyright American Chemical Society. 
 
 
produced by the nanoparticle-catalyzed oxidation of hydrazine. If a miRNA molecule 
does not hybridize with the probe, then the nanoparticles cannot conjugate to the miRNA, 
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thus an electrochemical signal will not result. In this approach, the signal transducer is 
chemically bound to the target rather than the oligonucleotide capture probe, which 
increases the sensitivity and selectivity of the assay. This method is simple, sensitive, and 
rapid for miRNA detection. Another attribute to using electrochemistry is the low cost of 
the assay, which combats expensive microarray fabrication devices.  
Hairpin probes, or molecular beacons (MB), are another tool for miRNA 
detection. MBs are stem-loop structures consisting of a double-stranded stem 
approximately 4-5 base pairs in length, containing a donor and quencher fluorophore at 
the 5’ and 3’ ends, along with a single-stranded loop complementary to the target DNA or 
RNA base sequence 72 (Figure 1.4A). In the absence of target the fluorescence of the 
donor is quenched, whereas in the presence of target, the annealing of the MB leads to 
separation of the donor and acceptor fluorophore, resulting in fluorescence emission upon 
excitation. MBs are also very selective, differentiating targets with as little as a single 
base mismatch. One of the problems of using MBs to detect miRNA is that the small size 
of miRNA forces the loop of the MB to be small in order to hybridize to the target 
miRNA. Due to the small size of the loop, the efficiency of the resulting fluorescence 
signal may be low, since the stems may be unable to dissociate from one another. 
Another disadvantage with using MBs for direct nucleic acid detection is no signal 
amplification, which limits sensitivity. To improve the signal amplification researchers 
have attached multiple fluorophores to the stems of MBs. Due to the ease of design of 
MBs and their ability to be employed in a mix-and-measure assay, this technique has 
significant potential in the development of miRNA detection assays. The concept of 
molecular beacons for miRNA detection has been utilized by Famulok and colleagues 73. 
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In this article, two separate methods were utilized: direct detection of target miRNA 
through hybridization of miRNA to MB (Figure 1.4A), or detection of miRNA through 
signal-amplifying ribozymes (Figure 1.4B). Using the ribozyme approach, a hairpin 
probe labeled with a donor and quencher fluorophore was utilized as a signal transducer. 
The basis of this assay is that a ribozyme, iHP-let-7 will catalyze the cleavage of the 
hairpin probe upon hybridization of the miRNA let-7 with its target. Once cleavage 
results, a fluorescent signal is obtained. A detection limit of 50 fmol miRNA was 
observed, which was an improvement over Northern blotting techniques that yield 
detection limits in the pmol range. For detection utilizing the MB without docking to a 
ribozyme, results were an order of magnitude lower in sensitivity compared to that using 
signal-amplifying ribozymes. There are drawbacks to the ribozyme method, however, 
when applied in situ. The ribozymes are subject to digestion through ribonuclease 
activity. In order to be applied in situ, the designed ribozymes must be engineered such 
that they are stable in the presence of ribonucleases.  
19 
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Figure 1.4 Hairpin-probe miRNA detection. A) Molecular beacons consisting of a stem and loop 
in absence and presence of miRNA target. The target hybridizes with the loop, separating the 
stem, resulting in an increase in fluorescence intensity. B) Signal-amplifying ribozyme approach 
in which target miRNA and a fluorophore/quencher hairpin probe hybridize with different regions 
of a ribozyme. The hybridization of miRNA target with ribozyme induces cleavage of the hairpin 
probe, resulting in an increase in fluorescence. Reprinted with permission from Reference 54. 
Copyright 2007 American Chemical Society. 
 
 
A miRNA detection method utilizing fluorescence correlation spectroscopy has been 
developed 74. In this method, oligonucleotide probes composed of DNA and LNA 
complementary to the 5’ and 3’ ends of target miRNA were labeled with Oyster 556 and 
Oyster 656, fluorescent probes which each produce spectrally distinct signals upon laser 
excitation (Figure 1.5). Once these probes react and hybridize with 50-100 ng total tissue 
miRNA, unbound probes are hybridized with fluorescent quenchers to minimize 
background. The resulting probe/miRNA hybridized molecule is passed through a 
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capillary where probes are excited via a series of lasers and fluorescence emission is 
recorded on a CCD (charge coupled device) camera. A defining attribute of this method 
is its ability to differentiate between single-base mismatches, as shown through the 
studies of the let-7 gene family members. Let-7a and let-7c differ by only one base, yet 
produce a three-fold difference in the number of coincident events counted by the CCD 
camera upon hybridization of let-7a labeled probe to let-7a and let-7c. Another positive 
result from this method lay in the ability to detect miRNAs in tissues which were 
previously not detected via microarrays or Northern blotting due to their low sensitivity.  
 


Figure 1.5 Fluorescence correlation spectroscopy-based miRNA detection. Two partially 
complementary fluorophore-labeled oligonucleotide probes hybridize with miRNA target, 
followed by laser excitation of fluorophores. The fluorescence confocal microscope detects 
miRNA based on the emission of the two fluorophores hybridized with miRNA target. 
Reproduced with permission from reference 55. Copyright 2008 Wiley-VCH Verlag GmbH & 
Co. KGaA. 
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In a method by Li and colleagues, cation exchange-based fluorescence is 
employed as a signal amplification method for miRNA detection 75 (Figure 1.6). In this 
particular method, the target miR21 was hybridized with a portion of an oligonucleotide 
capture probe, followed by hybridization of the capture probe with a CdSe ionic crystal-
labeled oligonucleotide probe adjacent to the miRNA target. Following ligation, silver 
ions are introduced to the system. Cation exchange occurs between the Cd2+ and the Ag+ 
ions. The Cd2+ ions then bind to a fluorogenic molecule Rhod-5N, resulting in enhanced 
fluorescence emission. This method produced a detection limit of 35 fM. This method 
also possessed single-nucleotide specificity, and was capable of detecting differential 
miR21 expression patterns between healthy and diseased cells. 
 

Figure 1.6 Cation exchange-based miRNA detection. Target miRNA hybridizes with a hairpin 
probe, separating the stem, which allows for CdSe-modified oligonucleotide to hybridize with the 
probe. Cation-exchange occurs upon addition of silver ions, releasing Cadmium ions. Cadmium 
ions bind to a fluorophore causing activation of the fluorophore, resulting in an increase in 
fluorescence signal. Reproduced with permission from Reference 75. Copyright 2009 American 
Chemical Society. 
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Another signal amplification-based method is displayed by Fang and colleagues. In this 
method, gold nanoparticles are employed for the detection of miRNA by surface plasmon 
resonance imaging 76 (Figure 1.7). First, LNA-modified capture oligonucleotides are 
immobilized on a gold film, followed by addition of miRNA target. The miRNA is 

Figure 1.7 Gold nanoparticle-based miRNA detection. miRNA target hybridizes with a tethered 
oligonucleotide capture probe. miRNA is directly modified through poly(A) polymerase-
mediated addition of a poly-adenine tail. Thymine-modified gold nanoparticles are added to the 
miRNA target, followed by surface plasmon resonance imaging to detect the miRNA. Reprinted 
with permission from Reference 76. Copyright 2006 American Chemical Society. 
 
 
directly modified through poly-adenylation by poly(A) polymerase. Next, thymine-
modified gold nanoparticles are added to the poly-adenylated miRNAs to result in 
multiple gold nanoparticles bound to each miRNA. This method resulted in a detection 
limit of 10 fM. 
Another solid-phase amplification-based enzymatic miRNA detection method is 
displayed in the RAKE (RNA-primed array-based Klenow enzyme) assay 77. In this 
method, two probes partially complementary to the miRNA target are utilized (Figure 
1.8). One probe, known as the invasive oligo, hybridizes with a portion of the miRNA, 
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and forms a hairpin shape, partially hybridizing with itself. The secondary oligo probe is 
also partially complementary to the miRNA target, flanking the invasive oligo. The 
secondary oligo contains an overlapping section, which hangs off of the miRNA target 
(Figure 1.8A). This overhang provides a substrate for a structure-specific 5’ nuclease. 
This nuclease enzyme cleaves the overhang portion of the secondary probe. Following 
cleavage, another reaction template with partial complementarity to the cleaved flap, 
hybridizes with the reaction template (Figure 1.8B). Next, an oligonucleotide probe 
containing a terminal fluorophore and internal quencher hybridize with the reaction 
template. This oligo probe has a small overhang which will serve as a substrate for 
nuclease cleavage. The cleavage releases the fluorophore, allowing for an increase in 
fluorescence intensity upon excitation. This method reported a detection limit in the 
attomole range, and is capable of selectively detecting mature miRNA, while not 
detecting precursor miRNA.  
The new and emerging methods have all addressed the potential difficulties with 
Northern blotting, qRT-PCR, microarrays, and flow cytometry; however, all of the 
potential detection methods have not been explored for miRNA detection. The following 
sections will provide insight into future directions in miRNA research and the gaps that 
still exist in miRNA analysis. 
Figure 1.8 RAKE-based miRNA detection. A) The miRNA target partially hybridizes with two 
oligos: the invasive oligo, and the probe, 
miRNA target. Cleavage results in the release of a 5’ flap single
reaction template partially hybridizes with two oligos: the released 5’ flap from the initial 
cleavage reaction, and a FRET oligo, which contains a fluorophore and an internal quencher. 
Prior to cleavage, the fluorophore fluorescence is suppressed by the quencher. Upon cleavage, the 
fluorophore is released, and therefore out of the quenching range of the quench
hybridized with the secondary reaction template. Fluorescence intensity is observed upon 
excitation of the free fluorophore.
University Press.
 
 
1.7 
The characterization of the role of miRNA in biology and medicine is now at the 
forefront of its research. 
responsible for diverse physiological functions from cancer suppression to keeping the 
latent Herpes-Simplex Virus cells infected.
both of which form hairpin structures and flank the 
-stranded oligo. B) A secondary 
 Figure adapted from reference 77. Copyright 
Future Developments in miRNA Research 
This tiny molecule, through its gene regulation activity, is 
 More and more, researchers are looking into 
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er which remains 
2004 Oxford 
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roles of miRNA in different cellular processes; however, this activity is not supported at 
the same pace by new detection technologies. A time-consuming Northern blotting 
method is the gold standard for accurate determination of miRNA. Microarray methods 
are rapid and provide for high throughput analyses, but are costly and have limited 
quantitation ability. Hybridization methods are promising but need further improvement 
in terms of ease of use and sensitivity. There is much room for progress in detection 
methods that are sensitive, accurate, and simple to use.  
Cellular regulations are dynamic processes, which can be affected by simple 
perturbations. Therefore, an ideal method for studying gene regulation by miRNA would 
provide for single cell direct monitoring of miRNA with high spatial and temporal 
resolution. Advances in microscopy techniques and availability of reporters with high 
quantum yield should make such detection possible. One of the issues that need to be 
solved is direct labeling of miRNA in living systems. Researchers have been working in 
the field of direct labeling in the living system 78; however, this task remains difficult. 
Another problem in single cell dynamic detection of miRNA that needs attention is the 
ability to detect changes in the level of miRNA, on top of the existing background level 
of miRNA. 
The development of computational programs to determine binding between 
miRNA and their respective mRNA targets is another open area of research. One 
example of such a program is MicroInspector 79. Using this program, miRNA binding 
sites are found based on a database of known miRNA/mRNA binding sites, binding 
strength of hybridization, examination of secondary structures, and the organism the 
miRNA originated from. With this information, the binding sites on mRNA for unknown 
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target miRNAs can be predicted. Other bioinformatics methods utilizing different 
demarcation criteria have been developed as well 80, 81. Although the binding between 
miRNA and its target mRNA occurs through base-pairing interactions, in mammals, it is 
not completely complementary. Other factors may assist in this binding such as various 
ligands and proteins. In addition, symmetric binding and strong interaction at the 5’end is 
preferred for miRNA-mRNA binding. Research efforts need to be targeted toward the 
development of computational methods that allow prediction of miRNA-mRNA binding 
followed by their experimental validation. In addition, these computational studies would 
prove highly beneficial in the design of novel therapies that target miRNA-mRNA 
binding interactions. 
MicroRNA expression levels are gaining popularity as signatures for clinical 
diagnostics. Existing miRNA detection methods are mainly used for research purposes 
and are not ideal for diagnostic use. In order for miRNA detection methods to be 
employed for diagnostic use, they need to be rapid, sensitive, specific, and require small 
sample size. In addition, these methods should be able to detect several miRNAs 
simultaneously yielding an expression profile. Establishing criteria for validation of these 
methods is also important before these methods can be used practically. Miniaturization 
and microfluidics have played a significant role in diagnostic field. There are many 
papers published on DNA and RNA detection based on microfluidics, some of which 
have been applied to microchips. For example, Baeumner and colleagues developed a 
microchip which could detect pathogens based on target mRNA sequences using 
fluorescence 82. Detection methods for miRNA could be easily adapted to microchip 
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platforms. The small sample volume and minimal assay time make the use of 
microfluidics a desirable method for miRNA-based diagnostics.  
Currently, miRNAs are studied only in terms of their biological role. Studies 
targeting their structure and mechanism of binding may shed light on their activity. In 
addition, the effects of small ligands as well as macromolecules on miRNA activity have 
not been studied. These types of fundamental evaluation can be performed through 
analytical techniques. We have reached a point where hundreds of different miRNAs 
have been discovered. It is well accepted that these tiny molecules are synthesized in 
cells for a purpose; however in order to decipher the role of these miRNAs in human 
health and in plant and animal biology, it is essential that the development of miRNA 
detection methods continues to progress.   
 
1.8 Gaps in miRNA Analysis 
Although methods for miRNA analysis are growing every day, there is a concern 
that these new methods are not standardized. Standardized methods must be reproducible, 
accurate, and robust. Also, standardized methods must have established normal levels of 
miRNA in the cell to determine whether the miRNA is upregulated or downregulated. 
Therefore, in order for miRNA detection methods to be reliable for medical diagnostics, 
standardization is necessary. Currently, Northern blotting is considered the gold standard 
for miRNA detection. This method, however, is time consuming, and has limited 
sensitivity. In order to detect miRNA with more sensitivity and apply these methods of 
analysis to practical applications, we must standardize newer, more sensitive miRNA 
detection methods by measuring a particular miRNA in multiple samples and comparing 
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the observed miRNA levels with known standards as provided by Northern blotting. 
Once standardized, these newer, more sensitive methods can be applied to measure lower 
concentrations of miRNAs which may not be detectable with Northern blotting. By 
further developing the newer analysis methods, it will be possible to replace time-
consuming methods with more time-efficient ones.  
In order to develop more sensitive detection methods, it is imperative that the 
marker which measures the miRNA levels has a very low detection limit. Both 
electrochemical methods and bioluminescence-based methods are highly sensitive and 
attractive alternatives to fluorescence-based methods. Bioluminescence-based methods 
are advantageous compared to fluorescence-based methods due to the fact that 
bioluminescence labels do not require an external energy source, and lack background 
noise, yielding higher sensitivity. Many bioluminescent proteins are comparable in size to 
commonly used fluorescent proteins such as GFP. Fluorescence-based methods utilizing 
quantum dots are also attractive due to high sensitivity and strong photostability of 
quantum dots, which is an advantage over commonly used small organic fluorophores.  
Another gap in miRNA analysis is the ability to perform multiplex analysis, or 
detect multiple miRNA molecules simultaneously. While microarrays can already 
accomplish this 83, many of the more recent miRNA analysis techniques have only 
reported on detecting a single miRNA. It is thus necessary to further develop these 
miRNA analysis methods to be capable of multiplex detection.  
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1.9 miRNA Detection Technologies Developed in This Dissertation 
While numerous methods for microRNA detection have been reported, there are 
virtually no examples in the literature employing bioluminescent labels outside of 
luciferase reporter bioassays 84, 85. Bioluminescence-based labels have multiple 
advantages, including the ability to emit light with no external energy source. In 
bioluminescent systems, the excitation energy is provided by a biochemical reaction 
resulting in emission of a photon. In the case of Renilla luciferase (Rluc), Rluc catalyzes 
the oxidative decarboxylation of coelenterazine to coelenteramide, which results in 
emission of photons of light at ~480 nm with native coelenterazine as a substrate 86 
(Figure 1.9). The advantage of no external energy source is an absence of background 
associated with the external source, a problem encountered with fluorescence-based 
applications. Along with an internal excitation source, bioluminescent labels have the 
advantage of being highly sensitive in terms of light output. It has been found that 
chemiluminescent and bioluminescent labels can detect biomolecules down to the 
attomole level 87. Bioluminescent labels also have the advantage of lack of toxicity. 
Bioluminescent proteins are routinely used in pharmacokinetic assays as reporters and do 
not result in altered cell activity. Due to the high sensitivity of bioluminescent-based 
labels, it is proposed that bioluminescence-based systems can be applied to miRNA 
detection for quantitative analysis. Conjugation of oligonucleotides which are specific to 
miRNA detection can be performed to allow for hybridization-based assays in both the 
solid phase and the solution phase. Incorporation of bioluminescent labels for miRNA 
detection will result in novel component technologies which can form a multifaceted 
toolkit for miRNA analysis.  
Figure 1.9 Coelenterazine reaction. 
coelenterazine to coelenteramide. This oxidation reaction releases CO

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The work that follows describes the component technology 
employing Rluc as a bioluminescent label for quantitative analysis of miRNA in a 
sensitive, specific, rapid manner. A solid
Rluc as a label for competitive hybridization between a biotinylated
two complementary strands: miRNA target, and a complementary Rluc
This method was applied 
bioluminescence resonance energy transfer 
employs Rluc as a BRET donor and 
detection method is introduced which employs hybridization
complementation between two fragments of Rluc
been employed for miRNA detection. A final, fluorescence
which is employed to detect dual miRNA targets. These new technolog
current miRNA detection technologies and can potentially be translated to the clinical 
setting for diagnostic purposes. 
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CHAPTER 2: SOLID-PHASE MICRORNA DETECTION  
 
2.1 Introduction 
MicroRNAs are considered useful diagnostic and prognostic markers, candidates 
for therapeutic intervention, and targets for basic biomedical research. The tremendous 
activity in the miRNA research field has fueled the need for experimental methods that 
are capable of quantifying miRNAs 91. Because of the emerging diagnostic value of 
miRNA it is critical that the methods for its detection are simple to use and highly 
sensitive. In that regard, a competitive solid-phase hybridization-based method has been 
developed for the detection of the microRNA, miR21 
(UAGCUUAUCAGACUGAUGUUGA) using the bioluminescent protein Renilla 
luciferase (Rluc) as a label and employed the method in the detection of miR21 in breast 
cancer cells.  
The solid-phase hybridization assays currently employed for miRNA detection 
have employed organic fluorophores, quantum dots, and gold nanoparticles as labels 70. 
These methods have provided a detection limit in the femtomole range and prove to be 
viable alternatives to the time-consuming Northern blotting method. One limitation of 
these methods, however, is that they require miRNA enrichment followed by labeling of 
miRNA isolated from the sample under study prior to detection. Therefore, there remains 
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a need for a miRNA detection method that is simple, rapid, and provides for 
measurement of miRNA directly from a cellular extract in a sensitive manner.  
The bioluminescent enzyme, Rluc, employed as a label in the following chapters, 
is a small, ~36 kDa protein that requires only the addition of coelenterazine for light 
generation 86, 92-94. Rluc catalyzes the oxidative decarboxylation of coelenterazine in the 
presence of molecular oxygen to coelenteramide 86. This process leads to emission of 
light that follows glow-type kinetics and has an emission wavelength maximum of 485 
nm 86. Several coelenterazine analogs have been synthesized with different properties in 
terms of emission wavelength, quantum efficiency, and cell permeability, thus enhancing 
the applications of Rluc 93. Since light generation occurs due to a chemical reaction there 
is no requirement for external excitation light, providing for the detection of Rluc activity 
with a high signal-to-noise ratio range 95. Additionally, due to availability of the Rluc 
gene for cloning, the protein can be reproducibly produced in unlimited amounts and 
fused to any desired molecule.  
In this study, an assay was developed for the detection of the microRNA, miR21, 
which has been linked to several cancers 96, 97. For example, levels of miR21 have been 
found to be elevated in breast, liver, ovarian, pancreatic, and brain tumors compared to 
their respective normal tissues 36, 96-99. Furthermore, blocking of miR21 using an 
antisense oligonuclotide resulted in the reduction of cancerous cell growth in vitro and in 
cell lines 96, 97. Therefore, availability of a sensitive assay for the detection of miR21 will 
be useful in diagnostics, basic research, and in designing drug therapy.  
In this study, the enzyme Rluc was obtained using genetic engineering tools and 
conjugated to an oligonucleotide probe corresponding to the sequence of miR21. A 
competitive assay was performed
miR21 probe to bind biotinylated anti
signal was measured after the addition of the Rluc substrate coelenterazine, and was 
correlated with the amount of free miR21 in the sample. The assay developed was also 
utilized to determine the level of miR21 expression in 
cancerous cells.  
 
Figure 2.1 miRNA solid-p
competitively hybridize with the anti
wash step followed by adding coelenterazine
Copyright 2008 American Chemical Society.
 
 
Reagents: Luria Bertani (LB) broth and agar were purchased from DIFCO Laboratories 
(Detroit, MI).  Ampicillin, bovine serum albumin 
R250 stain were obtained from Sigma Laboratories (St. Louis, MO). The high 
performance Ni+2-sepharose beads were purchased from GE Healthcare (Uppsala, SE). 
Coelenterazine (ctz) was purchased from Prolume (Pinetop, AZ). C
oligonucleotide probes were obtained from Operon Technologies (Huntsville, AL). 
 between miR21 from the sample and the Rluc
-miR21 oligonucleotide probe (Figure 
extracts of cancerous and
hase assay design. The Rluc-miR21 and miR21 
-miR21.  The luminescence signal can be measured after a 
. Reprinted with permission from Reference 88. 
 
2.2 Materials and Methods 
(BSA), and Coomasie Brilliant Blue 
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Ninety six-well neutravidin coated white microtiter plates and Sulfo-SMCC 
(Sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate were purchased 
from Pierce Technology (Rockford, IL). TRIZOL reagent and Trypsin-EDTA were 
purchased from Invitrogen (Carlsbad, CA). All of the buffers used for miRNA work were 
autoclaved and DEPC treated to protect from RNAse degradation.  
 
Apparatus: Bacterial cell cultures were grown in an orbital shaker, and centrifuged using 
a Beckman J2-MI centrifuge (Palo Alto, CA). Luminescence emission scans were 
obtained using the Varian Cary Eclipse Fluorescence Spectrophotometer (Palo Alto, CA). 
Luminescence intensity measurements were recorded using a Genios workstation 
luminometer (TECAN, NC). All luminescence intensities reported are the average of 
three replicates, and have been background corrected. UV-Visible absorbance 
measurements were performed using a Perkin Elmer UV/Vis/NIR LAMBDA 
spectrophotometer.  
 
Rluc Plasmid Construction: The gene for Rluc was isolated from the plasmid phRl-
CMV (Promega, WI) using polymerase chain reaction employing primers (RlucFor-5’-
GGTGGTGGATCCGATGGCTTCCAAGGTGTACGACCCCGAG-3’, RlucRev-5’-
GGTGGTGAATTCTTACTGCTCGTTCTTCAGCACGCGCTCC-3’) that also code for 
the restriction enzymes BamHI and EcoRI. The sequence coding for BamHI is underlined 
in the Forward primer, while the sequence coding for EcoRI is underlined in the Reverse 
primer. The plasmid pRsetB and the gene for Rluc isolated by PCR were digested with 
restriction enzymes BamHI and EcoRI and cloned into pRSetB (Invitrogen, Carlsbad 
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CA.) to construct the plasmid pSKD2. The ligated plasmid was transformed into E. coli 
cells strain 2566 (NEB Biolabs, MA). Gene sequencing and restriction analysis were 
performed to confirm the presence of the gene for Rluc. Gene sequencing results are 
shown in Appendix A. 
 
Rluc Expression: The cells containing the plasmid pSKD2 were grown in Luria Bertani 
(LB)-broth containing ampicillin (100 µg/mL) at 37oC to an optical density of 0.5 
measured at 600 nm. Protein expression was induced using IPTG (0.5 mM final 
concentration) and the cells were grown for an additional 3 h at 37oC. The cells were 
harvested by centrifugation at 16oC, 8600 x g, for 15 min and were sonicated for 5 min 
with a 20 s on and 20 s off cycle. The crude protein was obtained by centrifugation at 
16oC, 8600 x g, for 15 min.  
 
Rluc Purification: High performance nickel-bound sepharose column was prepared by 
washing with distilled water followed by equilibration with binding buffer (100 mM 
potassium phosphate buffer containing 250 mM NaCl, 0.6 mM NaN3, and 20 mM 
imidazole, pH 7.6). The crude Rluc protein in binding buffer was loaded onto the nickel-
bound sepharose column and incubated overnight at 4oC. The column was then washed 
with 20 mL of binding buffer followed by 20 mL of wash buffer (100 mM potassium 
phosphate buffer containing 250 mM NaCl, 0.6 mM NaN3, and 50 mM imidazole, pH 
7.6). Purified Rluc was then eluted with 5 mL of elution buffer (100 mM potassium 
phosphate buffer containing 250 mM NaCl, 0.6 mM NaN3, and 100 mM imidazole, pH 
7.6). Eluted fractions which showed luminescent activity were collected and the purity 
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was determined by SDS-PAGE using Coomassie staining solution. Protein concentration 
was determined by measuring absorbance at 280 nm employing an extinction coefficient 
of 62520 M-1cm-1 (www.luxbiotech.com/Docs/Nanolight/Renilla_luciferase.pdf).  
 
Labeling of Oligonucleotide Probes: The oligonucleotide probe complementary to 
miR21 (anti-miR21) was designed containing a biotin moiety at the 3’ end (5’-
TAGCTTATCAGACTGATGTTGA-biotin-3’). An oligonucleotide probe that has a 
sequence the same as miR21 was designed to contain an amino modification at its 3’end 
(5’-TCAACATCAGTCTGATAAGCTA-NH2-3’). This oligonucleotide probe was 
reacted with equimoles of sulfo-SMCC (1:1). The reaction was performed at room 
temperature for 30 min. Rluc was reduced by adding 80 mM TCEP. The reduced Rluc 
was added to the probe-linker mixture such that the ratio of Rluc to probe was 1:5. The 
reaction was performed for 30 min at room temperature and BSA was added to the 
reaction mix to achieve a final amount of 0.1% BSA. The unconjugated probe and sulfo-
SMCC was removed by dialysis against 100 mM potassium phosphate containing 250 
mM NaCl, 0.1% BSA, 0.6 mM NaN3 pH 7.4 to eliminate interference from unlabeled 
oligonucleotide. Removal of unconjugated probe is also necessary for the determination 
of concentration of Rluc-miR21 concentration. The concentration of Rluc-miR21 
conjugate was determined spectrophotometrically at 260 nm by following established 
protocol 100. A volume of 200 µL of miR21-Rluc probe was placed into a microtiter plate, 
and the emission scan of the protein was obtained after the addition of 0.5 µL of ctz (1 
mg/mL).  
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Hybridization Study: A 20 pmole/µL concentration of biotinylated-anti-miR21 probe 
was prepared in Rluc buffer (100 mM phosphate buffer containing 250 mM NaCl, 1 mM 
EDTA, and 0.1% BSA, pH 7.4). Serial dilutions of Rluc-miR21 probe were prepared 
using the Rluc buffer. A volume of 50 µL of biotin-anti-miR21 probe and 50 µL of 
varying concentrations of Rluc-miR21 probe were mixed together and incubated at 37oC 
for 30 min. At the end of 30 min, the probe mixture was placed in a neutravidin-coated 
microtiter plate pre-washed three times with a wash buffer (100 mM phosphate buffer 
containing 250 mM NaCl, 1 mM EDTA, and 0.5% BSA, pH 7.4) and incubated with 
shaking at room temperature for 1 h. A three-time wash step was performed using wash 
buffer.  Next, 200 µL of Rluc buffer and 0.5 µL of coelenterazine (ctz) were added to the 
plate and luminescence measurement was performed with a 100 ms integration time.  
 
Hybridization Time Study: The mixture of 50 µL biotinylated-anti-miR21 probe (20 
pmoles) and Rluc- miR21 probe total volume 50 µL (20 pmoles) was incubated at 37oC 
for 30 min and was immobilized on a neutravidin-coated microtiter plate for different 
periods of time. A wash step was performed to remove unbound probes. Luminescence 
intensity was measured after the addition of Rluc buffer and ctz.  
 
Dose-Response Curve for miR21: A mixture of biotinylated-anti-miR21probe (50 µL, 
20 pmoles), Rluc-miR21probe (25 µL, 20 pmoles), and 25 µL of varying concentrations 
of unlabeled miR21 DNA probe was incubated at 37oC for 30 min. Next, the mixture was 
added to the neutravidin coated plate and the immobilization step was performed at room 
temperature for 1 h with shaking. After 3-times wash step, 200 µL of Rluc buffer and 0.5 
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µL of ctz was added to the wells and luminescence measurement was performed. A dose-
response curve was generated for miR21 by plotting luminescence intensity against the 
concentration of miR21. Intra-assay precision was estimated by analyzing six replicates 
of three different miR21 concentrations (0.1, 1, 10 pmoles/well) in a single assay. Inter-
assay precision was determined by measuring three miR21 concentrations (0.1, 1, 10 
pmoles/well) in three separate assays. Next, a dose-response curve was generated using 
miR21 RNA probe. The procedure performed was the same as when using the miR21 
DNA probe.  
 
Recovery Study of miR21 in MCF-10A Cells: Cells from the human mammary 
epithelial cell line (MCF-10A) were obtained from the laboratory of Prof. Pamela 
Crowell’s at Indiana University Purdue University Indianapolis. Adherent cells were 
released by trypsin treatment and washed with autoclaved and DEPC treated 100 mM 
potassium phosphate buffer containing 100 mM NaCl, pH 7.4. The cellular extract was 
prepared using previously published protocol 101, 102. All of the buffers used for cellular 
extraction were autoclaved and DEPC treated to protect miRNA from RNAse 
degradation. The cell pellet was washed with buffer A (10 mM HEPES, pH 7.9 
containing 1.5 mM MgCl2, 10 mM KCl, and 0.5 mM DTT). The cells were resuspended 
in buffer B (20 mM HEPES, pH 7.9 containing 25% (v/v) glycerol, 0.42 M NaCl, 1.5 
mM MgCl2, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 0.5 mM 
DTT, and 0.1% Nonidet P-40) and incubated on ice for 15 min. The cell suspension was 
vortexed and centrifuged for 10 min at 4oC. The supernatant was diluted with buffer C 
(20 mM sodium phosphate, pH 7.5 containing 20% (v/v) glycerol, 0.1 M KCl, 0.2 mM 
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EDTA, 0.5 mM PMSF, and 0.5 mM DTT) and stored at -80oC until used. The cell extract 
after thawing was directly subjected to analysis in triplicate. For the recovery studies, 0.1, 
1, and 10 pmoles/well of miR21 was added to MCF10A total RNA. The concentration 
values of added miR21 were determined using the dose-response curve generated 
concurrently using standard amounts of miR21. Detection of miR21 was also performed 
from the same cell samples using extracted RNA. The total RNA was extracted using a 
previously published protocol 
(www.sanger.ac.uk/Projects/Microarrays/arraylab/protocol1.pdf). Briefly, the cell pellet 
was vortexed to break open cells. TRIZOL reagent was added to the cell pellet followed 
by incubation at room temperature for 5 min. RNA extraction was performed using 
chloroform followed by precipitation using isopropanol. A total of 10 µg of isolated RNA 
was employed in the assay. The amount of miR21 in MCF10A RNA was determined by 
generating a dose–response curve using standard amounts of miR21 probe.  
 
2.3 Results and Discussion 
Detection methods for microRNA that are highly sensitive and simple are in 
demand due to the emerging role of miRNA in several diseases and its significance in 
medical diagnostics. MicroRNAs can serve as early markers of cancer and hence have 
become a target of biomedical research. In this work, a sensitive detection method for the 
miRNA, miR21 based on the bioluminescence of Renilla luciferase has been developed. 
High signal-to-noise ratio achieved using the bioluminescence detection provides an 
advantage for the detection of miRNA in vitro and other sample matrices such as a 
cellular extract.  
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For this study, the gene for Rluc was cloned into the expression vector pRSetB 
and was expressed in E. coli cells. The protein was purified using nickel affinity 
chromatography. The amine-modified miR21 oligonucleotide probe was conjugated to 
Rluc through the sulfhydryl groups of cysteines present on Rluc. The conjugation was 
performed using a hetero-bifunctional linker SMCC
 
containing succinimide and 
maleimide functional groups. The conjugation of probe to Rluc did not affect the activity 
of Rluc as the luminescence emission profile and intensity was found to be similar to the 
unmodified Rluc. A biotinylated-oligonucleotide probe (anti-miR21) complementary to 
the miR21 sequence was synthesized chemically. First the hybridization study was 
performed to determine if labeling of miR21 probe with Rluc interferes with the 
hybridization to the anti-miR21 probe. For the hybridization study, various 
concentrations of Rluc-miR21 probe were mixed with biotinylated-anti-miR21 probe and 
incubated at 37oC for 30 min. The hybridized probe mixture was then added to a 
neutravidin coated plate to immobilize the probe on the wells of the plate through biotin-
neutravidin interactions (Figure 2.2). After a wash step to remove unbound probes, 
coelenterazine was added and luminescence intensity was monitored.  
Figure 2.2, depicting luminescence intensity against the concentration of miR21-
Rluc probe, shows that using a fixed concentration of the anti-miR21 probe and 
increasing the concentration of miR21-Rluc probe, resulted in a linear increase in 
intensity. This result indicates that the Rluc labeled oligonucleotide probe can hybridize 
effectively with its complementary probe. A hybridization time study was performed to 
determine the minimum time sufficient for hybridization to occur and the optimal 
temperature for the hybridization. From this study the hybridization time of 30 min and 
incubation at 37oC followed by immobiliz
optimal conditions for the study. 
 
Figure 2.2 Binding curve between miR21
data are based on an average response of three samples +/
permission from Refernce 88. Copyright 2008 American Chemical 
 
 
A dose-response curve was generated based on competition between miR21
and free miR21 DNA probe to hybridize with biotinylated
A synthetic DNA target was employed first due to its enhanced stability compared to 
RNA. The assay is designed 
free miR21 from sample to bind biotin
hybridization the sample mixture is added to the neutravidin coated plate where 
hybridized DNA binds through biotin
that the hybridization between probes can oc
design where hybridization occurs on a solid phase. 
ation on the plate for 1 h were chosen as the 
 
-Rluc probe and biotinylated anti-miR21 probe. The 
- the standard deviation.
Society. 
-anti-miR21 probe (
such that the competitive reaction between Rluc
-anti-miR21 occurs in a solution phase. After the 
-neutravidin interactions. Therefore, it is expected 
cur more efficiently compared to the assay 
The dose-response curve (Figure 
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 Reprinted with 
-Rluc 
Figure 2.3). 
-miR21 and 
2.3) 
shows that with an increasing concentration of free miR21 probe
intensity decreases. From this curve a linear range from 1 x 10
obtained, with the ability to detect 
assay precision was obtained
(Table 2.1). The calibration curve was generated and the concentrations of six replicates 
of samples containing 0.1, 1, and 10 pmoles of miR21/well were estimated.
 The inter-assay precision was evaluated from the measurement of 0.1, 1, and 10 
pmoles of miR21/well from three experiments performed on three different days (Table 
2.1). The precision of the assay was satisfactory with levels
dose-response curve was also generated using a miR21 RNA probe instead of a DNA 
probe (Figure 13). The dose
the dose-response curve generated using the miR21 DNA probe (Figure 
Figure 2.3 Dose-response curve for miR21 DNA target. The dose
by incubating a fixed amount of biotinylated anti
varying concentrations of miR21 DNA target probe. The data are based on an average 
three samples +/- the standard deviation. Reprinted with permission from Reference 88. 
Copyright 2008 American Chemical Society.
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 - 5 x 10
5 femtomoles (25 pM) of miR21. An estimate of intra
 by analyzing six replicate samples within a single assay 
 of variability below 10
-response curve as shown in Figure 2.4 correlates well with 
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-miR21 probe and miR21-
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response of 
Figure 2.4 Dose-response curve for miR21 RNA. The dose
incubating a fixed amount of biotinylated anti
concentrations of miR21 RNA target. The data are based on an average response of thre
+/- the standard deviation
American Chemical Society.
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Table 2.1 Solid-phase intra-
means of six determinations, and for inter
determinations. 
 
Intra-assay 
1 
2 
3 
Inter-assay 
1 
2 
3 
 
 
To demonstrate suitability of the assay developed i
real samples, analysis was performed 
non-tumorigenic human mammary epithelial
-response curve was generated by 
-miR21 probe and miR21-Rluc probes with varying 
. Reprinted with permission from Reference 88. Copyright 2008 
 
 and inter-assay precision. For intra-assay precision, the values are the 
-assay precision, the values are the means of three 
added (pmol/well) 
found 
(pmol/well) ± 
SD %CV
0.1 0.1 ± 0.002 
1 1.0 ± 0.02 
10 10.1 ± 0.6 
    
0.1 0.1 ± 0.004 
1 1.1 ± 0.04 
10 10.3 ± 0.8 
n the detection of miR21 in 
in a cellular extract. For this study, 
 cell line (MCF-10A) were utilized
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e samples 
 
2.0 
2.0 
5.9 
  
3.6 
3.6 
7.7 
extracts from a 
. The 
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level of miR21 in the MCF-10A cell extract was found to be 50 fmoles. It should be also 
noted that the bioluminescence signal obtained in the cell extract study was comparable 
to the in vitro assay, indicating no effect of the matrix on the signal. The accuracy of the 
method was also determined by measuring the recovery of known amounts of miR21 
spiked into the cellular extract. Data reported in Table 2.2 shows that the recovery was 
found to be between 97 and 103% for 0.1, 1, and 10 pmoles of miR21 spiked per well. 
This study demonstrates the feasibility of the assay developed in the detection of miR21 
directly from a cellular extract thereby reducing the sample preparation time.  
MCF-7 cells are a well-characterized estrogen receptor (ER) positive control cell 
line and therefore are a useful in vitro model of breast cancer. Levels of miR21 have been 
shown to be increased in breast cancer. Therefore, MCF-7 cells were employed to 
determine their levels of miR21 and compared these levels with that in MCF-10A cells 
which are primary epithelial non-tumorigenic cells. Two separate MCF-7 cultures were 
utilized and compared to MCF-10A samples (Figure 2.5). A 3-4 fold increase in the 
concentration of miR21 was observed in MCF-7 cells compared to MCF-10A cells. A 
%CV (coefficient of variation) for the miR21 determination ranged from 2-8%. This 
study demonstrates that the developed assay can be employed as a simple test to monitor 
expression of miRNA in cancerous vs. non-cancerous cells. Therefore, the method 
developed can be potentially employed as a diagnostic test for breast cancer that utilizes 
miR21 as a biomarker. 
 
Table 2.2 Solid-phase miR21 detection accuracy. 
cellular extract containing 50.0 pmoles of miR21, as previously determined, and the recovered 
amount of miR21 was determined from the dose
added miR21 
(pmol/well)
0.1 
1 
10 
 

 
Figure 2.5 Comparison of miR21 levels in MCF
levels. Error bars indicate the +/
employed with the total RNA extracted from MCF
miRNA that was present in each culture. 
Copyright 2008 American Chemical Society
 
 
A rapid and highly sensitive hybridization assay for microRNA, miR21 based on 
the bioluminescence of Renilla 
employ Rluc as a direct label for hybridization assays
employed Rluc mainly as a reporter for gene expression analysis. The bioluminescence 
emission, small size, and 
Synthetic miR21 RNA was added to MCF
-response curve. 
 
recovered 
(pmol/well) 
mean 
recovery (%) bias (%)
0.097 ± 0.003 97.0 -3.0
1.03 ± 0.04 103.0 3.0
10.14 ± 0.50 101.4 1.4
-7 cells vs. noncancerous MCF
- standard deviation values. The solidphase method was 
-10A and MCF-7 cells to quantify the miR21 
Reprinted with permission from Reference 88. 
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2.4 Conclusions 
luciferase has been developed. This is the first study to 
 for miRNA detection
the requirement for the addition of only coelenterazine make 
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Rluc an efficient label for hybridization assays. The hybridization method developed was 
applied for the determination of miR21 in both MCF-10A and MCF-7 cellular extract. 
The method developed was able to discriminate levels of miR21 in cancerous vs non-
cancerous cells, which can be a significant advantage in early cancer diagnosis. The need 
for the detection of early molecular markers in cancer diagnosis is immense, which can 
be potentially fulfilled by the availability of methods that are rapid and sensitive such as 
the one developed in this work. The method allowed sensitive, accurate, and precise 
measurement of miR21 in vitro as well as in cells. The availability of simple, rapid, and 
sensitive assays for microRNAs that provides for determination directly from a cell 
extract should prove valuable because of their potential as diagnostic markers for a 
variety of diseases including cancer. Furthermore, the method developed offers the 
advantage of parallel analysis in a 96-well microtiter plate and makes it suitable for 
application in clinical diagnostics and drug discovery. The advantages of the method 
developed in this work such as high signal intensity afforded by Rluc and minimal 
sample preparation enhances the suitability of this method for adapting to miniaturized 
analytical platforms providing for high sample throughput. Furthermore, recent findings 
in miRNA research areas indicate that miRNAs can be isolated from biofluids such as 
serum, plasma, saliva, and urine 103. The assay developed in this work can be easily 
applied to determination of miRNAs in these sample matrices if desired since 
bioluminescent proteins have been employed previously in saliva and blood analysis of 
physiological molecules 104, 105. 
 

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CHAPTER 3: BIOLUMINESCENCE RESONANCE ENERGY TRANSFER (BRET)-
BASED DETECTION 



3.1 Introduction 
Thus far, a solid-phase method for miRNA detection has been described which is 
capable of detecting miRNA in the femtomole range. Due to the washing steps required 
to remove unbound probe inherent to solid-phase assays, the total assay time is increased. 
In order to develop a more rapid, simple method for miRNA detection, and to increase 
the available component technologies for nucleic acid detection employing Rluc, a 
solution-phase method has been developed incorporating Rluc and quantum dots as 
labels. Like all hybridization-based detection assays, a change in signal must result from 
the hybridization event. Due to the fact that Rluc signal will not change in the solution-
phase when conjugated to a single oligonucleotide probe and hybridized with a 
complementary oligonucleotide probe, an alternative method must be developed which 
can transfer the hybridization event into a measurable signal. To accomplish this task, 
bioluminescence resonance energy transfer can be employed such that hybridization leads 
to a transfer of energy from donor to acceptor. BRET, which is similar to fluorescence 
resonance energy transfer (FRET), occurs when energy is transferred from a donor to 
acceptor. What differentiates BRET from FRET, is in the donor. A BRET donor is not 
excited through an external source, rather energy is generated through a biochemical 
reaction between the BRET donor and a substrate 106. The luminescence emission peak of 
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Rluc in the presence of native coelenterazine is approximately 485 nm, which overlaps 
well with the absorption of QDs in the 300-500 nm range. Therefore, employing Rluc and 
quantum dots as a bioluminescence resonance energy transfer (BRET) donor and 
acceptor, respectively for the detection of miRNA was performed. 
The use of QDs as BRET acceptors and their application in hybridization-based 
miRNA detection can have several advantages. QDs have attracted much interest as 
labels because of their desirable properties, including high quantum yields, high 
photostability, and tunable sharp spectral emission 107-109. However, the requirement of 
excitation of QDs from an external source can be a disadvantage due to the associated 
background signal 110. If excitation of QDs can be achieved using a chemical reaction that 
occurs in a bioluminescent system as demonstrated in this work, the background problem 
from an external excitation source can be overcome. The background signal associated 
with the detection of a bioluminescence signal is insignificant. Additionally, the use of 
QDs opens the possibility of multiplex nucleic acid detection by taking advantage of their 
wide array of emission wavelengths which can be excited internally through Rluc. Due to 
the fact that QD emission wavelengths are sharp, spectral deconvolution will not be a 
difficult task, as this has been demonstrated previously 110. 
The method developed in this work for nucleic acid detection is a rapid method 
that does not require separation of unhybridized probes. The use of QDs as BRET 
acceptors also overcomes the problem encountered when using fluorescent proteins as 
acceptors where the broad emission of fluorescent proteins overlap with the emission of 
Rluc, reducing the sensitivity of detection. While Renilla luciferase has been employed in 
numerous studies to measure protein-protein interactions 106, 111, 112, only a small number 
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of methods have employed Rluc as a BRET donor in nucleic acid detection assays 113. 
There are no known methods which employ the Rluc and QD as a donor and acceptor for 
nucleic acid detection. 
The presented work utilizes a competitive assay such that in the absence of target 
nucleic acid, complementary oligonucleotide probes labeled with Rluc and QD hybridize 
with each other bringing the two labels in close proximity. Upon addition of 
coelenterazine, the Rluc emits light at 485 nm which is absorbed by the QD, which in 
turn emits light at 710 nm. In the presence of target DNA, the target and Rluc-labeled 
probe compete to hybridize with the QD-labeled probe, thus lowering the emission 
intensity observed at 710 nm. This decrease in signal can be correlated with the amount 
of target nucleic acid present in the sample (Figure 3.1).  
 
 
Figure 3.1 Bioluminescence resonance energy transfer (BRET)
result of bringing Rluc and QD within close proximity upon hybridization and addition of 
coelenterazine. B) The result of the competitive hybridization between target present in the 
sample and the QD
TAGCTTATCAGACTGATGTTGA
[Reprinted with kind permission from Springer Science 
Vol 391 2008 2577-2581.] 
 
Reagents: Luria Bertani (LB) broth and agar were purchased from DIFCO Laboratories 
(Detroit, MI). Ampicillin, bovine serum albumin (BSA), and Coomassie Brilliant 
R250 stain were obtained from Sigma Laboratories (St. Louis, MO). Carboxylated 
quantum dot, QD705, was obtained from Invitrogen (Carlsbad, CA). The high 
performance Ni+2-sepharose beads were purchased from GE Healthcare (Uppsala, SE). 
Native coelenterazine (ctz) was purchased from Prolume (Pinetop, AZ). Chemically 
synthesized oligonucleotide probes as well as site
obtained from Operon Technologies (Huntsville, AL). 96
-based detection assay. 
-probe, disrupting the BRET signal. 
-3’, CT1 5’-TCAACATCAGTCTGATAAGCTA
+ Business Media: Anal Bioanal Chem 
 
3.2 Materials and Methods 
-directed mutagenesis primers were 
-well microtiter plates, 
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A) The 
T1 5’SH-
-NH2 3’. 
Blue 
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Sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (Sulfo-SMCC) and 
1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) were purchased from Pierce 
Biotechnology (Rockford, IL). E. coli strain ER2566 was purchased from New England 
Biolabs (Ipswich, MA). The phRl-CMV plasmid was purchased from Promega (Madison, 
WI). 
 
Rluc plasmid construction: The plasmid phRl-CMV was used for protein expression. In 
order to perform purification, a 6x histidine was added to the Rluc gene via site-directed 
mutagenesis using the following primers: Rluc His Tag Forward and Rluc His Tag 
Reverse. The bases coding for the histidine tag are underlined. An EcoRI site was added 
to the 3’ end of the histidine coding region for further utility (See Chapter 4). EcoRI site 
nucleotides are italicized (Table 3.1). The mutated plasmid was transformed into E. coli 
cells strain ER 2566.  Gene sequencing and restriction analysis were performed to 
confirm the presence of the 6x histidine tag (Appendix B).  
 
Table 3.1 Renilla luciferase + histidine tag site-directed mutagenesis primers 
Rluc His Tag 
Primers Primer Sequence 
Rluc His Tag 
Forward 5’-CTAGCCACCATGCATCACCATCACCATCACGAATTCGCTTCCAAGGTGTAC-3’ 
Rluc His Tag 
Reverse 5’-GTACACCTTGGAAGCGAATTCGTGATGGTGATGGTGATGCATGGTGGCTAG-3’ 
 

Rluc expression and purification: The cells containing the phRL-CMV plasmid were 
grown in Luria Bertani (LB)-broth containing ampicillin (100 µg/mL) at 37oC to an 
optical density of 0.5 measured at 600 nm. Protein expression was induced using IPTG 
(0.5 mM final concentration) and the cells were grown for an additional 3 h at 37oC. The 
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cells were harvested by centrifugation at 16oC, 8600 x g, for 15 min and were sonicated 
for 5 min with a 20 s on and 20 s off cycle. The crude protein was obtained by 
centrifugation at 16oC, 50000 x g, for 15 min. For purification of Rluc, a high 
performance nickel-bound sepharose column was prepared by washing with distilled 
water followed by equilibration with binding buffer (100 mM potassium phosphate buffer 
containing 250 mM NaCl, 0.6 mM NaN3, and 20 mM imidazole, pH 7.6). The crude Rluc 
protein in binding buffer was loaded onto the nickel-bound sepharose column and 
incubated overnight at 4oC while shaking. The column was then washed with 20 mL of 
binding buffer followed by 20 mL of wash buffer (100 mM potassium phosphate buffer 
containing 250 mM NaCl, 0.6 mM NaN3, and 50 mM imidazole, pH 7.6).  Purified Rluc 
was then eluted with 5 mL of elution buffer (100 mM potassium phosphate buffer 
containing 250 mM NaCl, 0.6 mM NaN3, and 100 mM imidazole, pH 7.6). Eluted 
fractions which showed luminescent activity were collected. Purified protein was 
dialyzed against 100 mM potassium phosphate, 250 mM NaCl, pH 7.6 to remove 
imidazole and NaN3 for conjugation reactions. Protein concentration was determined by 
measuring absorbance at 280 nm employing an extinction coefficient of 62520 M-1cm-1 
(www.luxbiotech.com/Docs/Nanolight/Renilla_luciferase.pdf).  
 
Rluc and QD oligonucleotide probe conjugation: The Rluc was conjugated to the thiol-
modified T1 oligonucleotide probe (5’-SH-TAGCTTATCAGACTGATGTTGA-3’) 
using the heterobifunctional linker Sulfo-SMCC. Rluc and Sulfo-SMCC were mixed 
together and allowed to react for 2 h at room temperature while stirring. Next, the excess 
Sulfo-SMCC was dialyzed out of solution against PBS buffer (25 mM sodium phosphate, 
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100 mM NaCl, 1 mM Na2EDTA, pH 7.4). After dialysis, T1 probes were added to a 
stirring Rluc-SMCC and reacted at 4oC overnight while stirring, followed by dialysis to 
remove unbound T1 probe against the same PBS buffer. For the conjugation reaction, 
mole ratios of Rluc: Sulfo-SMCC: Thiol-probe were 1:80:4, respectively. Due to the low 
concentration of the Rluc (2.9 µM), a large excess of crosslinker was used. The 
luminescence scan and intensity measurements were performed using the Rluc-T1 probe 
employing a Cary Eclipse spectrophotometer (Varian, CA). The carboxy-activated 
QD705 was conjugated to the amine-modified CT1 probe (5’-
TCAACATCAGTCTGATAAGCTA-NH2-3’) in the presence of 1-Ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC) and reacted for 2 h at room temperature 
while stirring in 10 mM borate buffer pH 7.4. The mole ratios of QD705: EDC: Amine-
probe were 1: 7.5: 1.5, respectively.  The activity of the QD-CT1 was monitored by direct 
excitation of QD705.  The fluorescence was measured using an excitation wavelength of 
485 nm while scanning the emission from 650-750 nm. 
 
Non-specific BRET study: Equimoles (4 pmoles) of non-conjugated Rluc in 
hybridization buffer (50 mM borate buffer pH 8.0 containing 0.1% BSA) and non-
conjugated carboxy-activated QD705 in 10 mM borate buffer pH 7.4 containing 0.1% 
BSA were mixed together to analyze whether BRET can occur from Rluc to QDs in the 
absence of oligonucleotide hybridization. Solutions of Rluc and QDs were mixed 
together and ctz (0.5 µL of 1 mg/mL) was added. The luminescence scan was obtained 
spanning a spectral range of 450-750 nm.

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Hybridization study: Initially, BRET from Rluc to a quantum dot was investigated upon 
probe hybridization. To achieve that, 4 pmoles of the Rluc-T1 probe and the QD705-CT1 
probe in 200 µL of hybridization buffer were mixed. The mixture was incubated at 37oC 
for 30 min and was allowed to cool down to room temperature before the addition of the 
substrate coelenterazine. A luminescence emission scan was obtained and the light 
intensity counts were measured at 485 nm corresponding to the Rluc emission and 710 
nm corresponding to the QD705 with a 1000 ms signal integration time. Several controls 
were monitored along with the sample. These controls include, (1) buffer + ctz, (2) buffer 
+ QD705-CT1+ ctz, (3) buffer + RLuc-T1 + ctz, (4) buffer + Target + RLuc-T1 + ctz. 
 
Calibration study: A calibration study was performed using 4.0 pmoles of the Rluc-T1 
and QD705-CT1 probes and by changing the amount of the unlabeled target probe 5’-
TAGCTTATCAGACTGATGTTGA-3’, (4, 8, 12, 16, 20, and 26 pmoles). Probe mixture 
in 200 µL of hybridization buffer was incubated at 37oC for 30 min and was allowed to 
cool down to room temperature before the addition of the substrate ctz. Luminescence 
intensity counts were measured at 485 nm and at 710 nm with a 1000 ms signal 
integration time. BRET ratio (Intensity485nm/Intensity710nm) was plotted against the 
concentration of the target.  
 
Hybridization in cellular extract: 4 pmoles of Rluc-T1 and QD705-CT1 were premixed 
with E. coli strain ER2566 extract to mimic the cellular environment. The ER2566 cell 
extract was prepared by growing the strain in LB media up to an optical density of 0.9 
measured at 600 nm. The cells were sonicated with a 20 s on and 20 s off cycle for 5 min 
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in 10 mM borate buffer, pH 7.4. The resulting mixture was directly used as an extract. 
The sample was hybridized at 37oC for 30 min. A luminescence scan was obtained after 
the addition of ctz spanning 450-750 nm.  
 
3.3 Results and Discussion 
The application of nucleic acid-based assays continues to expand into medical, 
forensic, and environmental fields. Nucleic acids do not have intrinsic properties that are 
useful for their direct detection; hence their detection requires the use of a reporter label. 
A majority of the label-based assays require separation steps, which makes these assays 
time-consuming. Here, a rapid, single-step nucleic acid detection method based on BRET 
from Rluc to quantum dots has been developed. 
In this proof-of-concept, a model DNA oligonucleotide corresponding to the 
microRNA miR-21, (5’-TAGCTTATCAGACTGATGTTGA-3’) was employed as a 
target nucleic acid sequence. A probe complementary to the target (CT1) was labeled 
with carboxy-activated QD705 using EDC chemistry. Another probe (T1), with the same 
sequence as the target was designed and labeled with Rluc through the heterobifunctional 
crosslinker Sulfo-SMCC.  
In BRET-based assays, the spatial orientation of the BRET donor and acceptor is 
an important consideration. The efficiency of BRET is dependent on the distance 
between the donor and acceptor molecules 114. In particular, BRET efficiency (E) is 
proportional to the inverse 6th power of the distance between the two molecules (r), as 
seen in the following equation: 
E= R06/ (R06 + r6) 
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Where R0 is the Förster distance (the distance in which energy transfer between the donor 
and acceptor is 50%). The Förster distance can be described by the following equation: 
R0= 9.78 x 103 (ΦD K2 n-4 J)1/6 
Where ΦD is the quantum yield of the donor, K is the orientation factor, n is the refractive 
index of the medium in which the hybridization is taking place, and J represents the 
overlap integral obtained from measuring the area beneath the overlapping portion of the 
donor fluorescence curve and absorption acceptor curve. Therefore, according to the 
resonance energy transfer efficiency equation, the closer the BRET donor and BRET 
acceptor (within 1-10 nm), the greater the BRET efficiency 115. Because of this fact, the 
labels on the oligonucleotides were placed such that they were adjacent to one another 
upon hybridization rather than end-to-end.  
Upon mixing Rluc-T1 and QD-CT1, it is expected that probe hybridization will 
occur, bringing the Rluc and QD within close proximity. Upon addition of ctz, the Rluc 
will emit bioluminescence with a peak at 485 nm, which will excite the QD, resulting in a 
710 nm emission referred to as the BRET signal (Figure 3.1A). Upon simultaneous 
mixing of target DNA with the Rluc-T1 and QD-CT1, a competitive reaction occurs in 
which the target and Rluc-T1 probe compete to hybridize with the QD-CT1. Using a 
fixed amount of QD-CT1 and Rluc-T1 probe and adding increasing amounts of target 
probe, the BRET signal is expected to decrease because of hybridization of target probe 
to QD-CT1 probe (Figure 3.1B).  
To evaluate the generation of BRET upon mixing of labeled probes, equimole 
amounts (4 pmoles) of Rluc-T1 probe and QD-CT1 probe were hybridized for 30 minutes 
at 37oC in hybridization buffer. The substrate coelenterazine (ctz) was added, and 
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luminescence was recorded from 450 to 750 nm. Since there was no target present in the 
sample, once ctz is added it is expected that a portion of the Rluc-T1 emission will be 
absorbed by QD-CT1, resulting in two peaks, one at 485 nm, corresponding to the Rluc, 
and another at 710 nm, corresponding to the BRET signal associated with the emission of 
QD705. As can be seen in Figure 3.2A, BRET occurs in the absence of target DNA. 
Several blanks were performed to assure that nonspecific BRET signal did not occur 
when ctz was added. 
Since it is evident that BRET does occur upon QD-CT1 and Rluc-T1 
hybridization, a calibration plot was developed in order to determine the relationship 
between the BRET ratio and the amount of target present in the sample (Figure 3.2B). 
The BRET ratio was determined by dividing the emission intensity at 485 nm by the 
emission intensity at 710 nm. To obtain luminescence intensities at 485 nm and 710 nm, 
point readings at these wavelengths were recorded instead of obtaining full luminescence 
scans. Figure 3.2B shows that as the amount of target DNA in the sample increases, 
emission from the QD decreases, resulting in a higher BRET ratio. This agrees with the 
initial hypothesis that competition from the target probe will prevent the QD-CT1 and 
Rluc-T1 probes from hybridizing, thus decreasing the emission intensity observed at 710 
nm. Through increasing the amount of target in the sample, the QD-CT1 emission will 
decrease, and since the Rluc-T1 emission energy is not absorbed by the QD-CT1, the 
Rluc-T1 emission intensity will increase. Therefore, an increase in emission intensity at 
485 nm, coupled with a decrease in emission intensity at 710 nm, will result in the 
increase in BRET ratio with increasing amounts of target probe. The results in Figure 
16B show that as little as 4 pmoles of target DNA can be detected in solution with only a 
30 min hybridization time.
Figure 3.2 BRET luminescence scan and calibration curve. 
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The relative peak heights in the two sample matrices were nearly the same as well.  A 
comparison of the normalized light intensity ratio of 485 nm/710 nm in the buffer matrix 
and in the E. coli cell matrix showed an approximately 9% decrease from buffer matrix to 
cellular matrix. Therefore, this detection assay is compatible in more complex cellular 
matrices.  

Figure 3.3 BRET luminescence scan in cellular extract. The BRET assay was performed in E. coli 
ER2566 cellular extract to determine if BRET is hindered in a more complex matrix. Equimole 
amounts of Rluc-T1 and QD-CT1 (4 pmoles) were mixed together at room temperature for 30 
min. [Reprinted with kind permission from Springer Science + Business Media: Anal Bioanal 
Chem Vol 391 2008 2577-2581.]  
 
 
3.4 Conclusions 
The results show that as little as 4 pmoles of target nucleic acid corresponding to 
miR21 can be detected in solution with only a 30 min hybridization time. This study 
represents a proof-of-concept for the rapid, sensitive detection of nucleic acids utilizing a 
quantum dot and Renilla luciferase as a BRET acceptor and donor, respectively. This 
method is an improvement over common solid-phase methods in that no wash steps to 
eliminate unbound probe are needed. While BRET was shown to work efficiently 
between the Rluc and QD, it is possible that the BRET efficiency can be improved with 
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smaller diameter quantum dots due to a decrease in the distance between donor and 
acceptor. This BRET-based method also has the potential to be employed for the 
detection of larger nucleic acid sequences through adjacent hybridization of Rluc-T1 and 
QD-T2 probes. Through adjacent hybridization instead of hybridization of Rluc-probe 
and QD-probe complementary to one another, an increase in QD signal will be observed 
upon addition of ctz instead of a decrease in QD signal that is observed in this method.  

 
 
 
 
 
 
 
 
 
 

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CHAPTER 4: PROTEIN REASSEMBLY-BASED DETECTION 
 
4.1 Introduction 
As demonstrated in previous chapters, the utility of Renilla luciferase is quite 
diverse, from applications as a reporter in gene expression and pharmacokinetics studies, 
to solid-phase and solution-phase hybridization labels. One area which has not been 
widely explored with Rluc is a process known as protein complementation. Protein 
complementation involves the genetic modification of proteins to produce non-
luminescent fragments capable of reorganizing into an active bioluminescent protein. In 
order to expand the component technology available for miRNA analysis, it becomes a 
logical step to consider the impact of protein complementation of Renilla luciferase and 
its application in miRNA detection. In that light, a method has been developed to detect 
miRNA based on protein complementation of two genetically modified Renilla luciferase 
fragments.  
The split protein complementation method has found applications as a 
biochemical tool to detect specific protein-protein and protein-nucleic acid interactions 
116-123
. In this method, two rationally designed fragments of a reporter protein are fused to 
proteins which interact with each other. The fragments in isolation are inactive; however, 
non-covalent biomolecular interactions between fused interacting proteins lead to the 
formation of an active reporter, allowing for the detection of protein-protein interactions. 
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This strategy has been successfully utilized in the reassembly of reporter proteins, 
specifically, dihydrofolate reductase, β-lactamase, β-galactosidase, ubiquitin, 
aminoglycoside kinase, Renilla luciferase, firefly luciferase, red fluorescent protein,  
green fluorescent protein (GFP), yellow fluorescent protein (YFP), and Gaussia 
luciferase 119, 120, 124-133.  
There is only one report on protein reassembly achieved through nucleic acid 
hybridization using split GFP as the reporter 134. In this study, reassembly of split GFP 
upon formation of a hybrid between two complementary oligonucleotides at a 200 
nanomolar concentration was accomplished. Design and development of fluorescent 
proteins such as GFP has revolutionized the biochemical field; however, as discussed in 
chapter one, these proteins have some limitations because of the requirement of high 
energy excitation and high background signal, reducing the sensitivity of the signal 
measurement. In that respect, bioluminescent proteins are a viable alternative since they 
do not require a high energy excitation source and do not suffer from background noise in 
signal measurement 87, 135-138. In a recent paper by Porter et al., these advantages of the 
bioluminescent enzyme firefly luciferase (Fluc) were utilized to detect proteins, small 
molecules, RNA, and double stranded DNA, both methylated and nonmethylated 139; and 
also have been utilized as a sensor for protease activity 140. This was accomplished 
through the expression of the Fluc fragments flanked by expressed protein domains, 
which when bound to the specific target, brought the split Fluc fragments within close 
proximity. This allows for protein reassembly to occur, resulting in a luminescent signal 
upon the addition of luciferin, the substrate for Fluc. In the case of nucleic acid detection, 
this method is not a hybridization-based assay that works for any target nucleic acid. This 
method will work only for targets for 
be engineered. Taking this into consideration, a proof
apply Renilla luciferase 
reassembly of split Rluc fragments 
of this method was evaluated with the detection of a target nucleic acid mimicking the 
sequence of the microRNA miR21.
Figure 4.1 Schematic representation of the Rluc 
oligonucleotide probe hybridization
2009 American Chemical Society.
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TCAACATCAGTCTGATAAGCTA-Thiol-3’, and free Probe 1, 5’-
TAGCTTATCAGACTGATGTTGA-3’) were obtained from Operon Biotechnologies 
(Huntsville, AL). Luria Bertani (LB) broth and agar were purchased from DIFCO 
Laboratories (Detroit, MI). The Hi-Trap copper chelating columns (1 mL) were 
purchased from GE Healthcare (Piscataway, NJ). Ampicillin, bovine serum albumin 
(BSA), and Coomasie Brilliant Blue R250 stain were obtained from Sigma Laboratories 
(St. Louis, MO). Protein molecular weight marker was purchased from Fisher Scientific. 
Coelenterazine (ctz) was purchased from Prolume (Pinetop, AZ). 96-well Neutravidin 
coated white microtiter plates and 1,8-bis-Maleimidotriethylene glycol (BM(PEO)2) were 
purchased from Pierce Technology (Rockford, IL).  
 
Apparatus: Bacterial cell cultures were grown in a Fisher Scientific orbital shaker, and 
centrifuged using a Beckman J2-MI centrifuge (Palo Alto, CA). Luminescence emission 
scans were obtained using the Varian Cary Eclipse Fluorescence Spectrophotometer 
(Palo Alto, CA). Luminescence intensity measurements were recorded using a Genios 
workstation luminometer (Tecan, NC). All luminescence intensities reported are the 
average of three replicates, and have been background corrected.  
 
Construction of Rluc split fragments: The gene for Rluc from the plasmid phRl-CMV 
was employed as the initial template. Before constructing fragments of Rluc, a non-
cleavable N-terminal 6x histidine tag was introduced on the Rluc gene to aid in protein 
purification, as well as a recognition site for EcoRI restriction enzyme cleavage. The 6-
histidine tag and EcoRI site were introduced using site-directed mutagenesis using the 
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primers Rluc His Tag Forward and Rluc His Tag Reverse, which can seen in Table 3.1. 
In order to perform site-directed mutagenesis, primers were added to the template phRL-
CMV, along with DNA polymerase and deoxynucleotide triphosphates (dNTPs). Next, 
polymerase chain reaction (PCR) was performed for 25 cycles to copy the new plasmid. 
Following PCR, the sample was digested with DpnI enzyme to digest plasmids that did 
not contain the added DNA. The mutated plasmid (pRluc-HisTag) was transformed into 
E. coli cells strain ER 2566, plated on LB agar supplemented with 100 µg/mL ampicillin, 
and DNA was isolated from the colonies via mini-preparation to perform gene 
sequencing and restriction analysis.  
 
Table 4.1 Primers for split luciferase plasmid design 
N-terminal 
Fragment 
Primers Primer Sequence  
Big Lux 
Forward 5’-GTTAAGGGAGGCAGTGGAGGTGGAGGTAGTTGTTAGTAAAAGCCCGACGTC-3’ 
Big Lux 
Reverse 5’-GACGTCGGGCTTTTACTAACAACTACCTCCACCTCCACTGCCTCCCTTAAC-3’ 
    
C-terminal 
Fragment 
Primers   
Small Lux 
Forward 5’-GTTAAGGGAGGCGAATTCTGTAGTGGAGGTGGAGGTAGTAAGCCCGACGTC-3’ 
Small Lux 
Reverse 5’-GACGTCGGGCTTACTACCTCCACCTCCACTACAGAATTCGCCTCCCTTAAC-3’ 

 
In order to genetically engineer the plasmid to code for the N-terminal Rluc 
fragment (amino acids 1-229), two stop codons were added between the codons for 
amino acids Gly229 and Lys230, using the plasmid pRluc-HisTag as the template DNA. 
Along with the stop codons, the DNA coding for a flexible linker (Ser Gly Gly Gly Gly 
Ser) and for a cysteine residue was added via site-directed mutagenesis as described 
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previously. The primers which coded for the stop codons, flexible linker, and cysteine to 
construct the N-terminal fragment are referred to as Big Lux Forward and Big Lux 
Reverse. The primer sequences are shown in Table 4.1. The bases coding for the stop 
codons are underlined, and the flexible linker and cysteine codons are italicized. After 
site-directed mutagenesis, the mutated plasmid was transformed into ER 2566 competent 
cells, followed by minipreparation, restriction analysis, and gene sequencing to confirm 
the presence of the stop codons, flexible linker, and cysteine codons (Appendix C). The 
purpose of the flexible linker was to allow the oligo-Rluc fragments to come into close 
proximity, while decreasing the amount of strain on the Rluc fragments caused by the 
oligonucleotide hybridization. The cysteine residue is present to provide an accessible 
thiol moiety through which conjugation to thiol-modified oligonucleotide probes can 
occur. A diagram explaining the steps of N-terminal fragment engineering can be seen in 
Figure 4.2A. 
In order to genetically engineer the plasmid coding for the C-terminal fragment 
(amino acids 230-311), a recognition site for EcoRI cleavage was added via site-directed 
mutagenesis between the codons coding for amino acids Gly229 and Lys230, using 
plasmid pRlucHisTag as the template. Also, a flexible linker and cysteine residue were 
added adjacent to the EcoRI cleavage site, on the N-terminal side of the C-terminal 
fragment (Figure 4.2B).  
The primers were used for the addition of the EcoRI cleavage site, linker, and 
cysteine, referred to as Small Lux Forward and Small Lux Reverse, are seen in Table 4.1. 
The bases coding for the EcoRI site are underlined, and the linker and cysteine-coding 
DNA is italicized. After site-directed mutagenesis was performed, followed by Dpn1 
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digestion, the new plasmid transformed into ER 2566 cells. Minipreparation was 
performed to isolate the plasmid, followed by restriction analysis with EcoRI, and gene 
sequencing in order to confirm the addition of the EcoRI site, the linker, and the cysteine 
residue. Upon verification of the mutated plasmid, digestion with EcoRI was performed 
to cut the plasmid, resulting in two DNA fragments, one fragment representing the N-
terminal fragment, and the other representing the linker, cysteine, and C-terminal 
fragment. After gel extraction, the C-terminal fragment was ligated to form the plasmid 
coding for C-terminal split Rluc (Figure 4.2B). Gene sequencing and restriction analysis 
with EcoRI were performed again to verify that the C-terminal fragment plasmid did not 
contain the N-terminal fragment gene (Appendix C). Once verified, the plasmid was 
transformed into ER 2566 competent cells for protein expression. 
 
 
 
 
 
 
 
 
 
A 
 
B 
Figure 4.2 Split luciferase plasmid construction.
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ampicillin (100 µg/mL) at 37oC to an optical density of 0.5 measured at 600 nm. Protein 
expression was induced using IPTG (1 mM final concentration) and the cells were grown 
for 24 h at room temperature. The cells were harvested by centrifugation at 16oC, 8600 x 
g for 15 min, resuspended in PBS buffer (50 mM sodium phosphate buffer, pH 8.0 
containing 300 mM NaCl), and were sonicated for 3 min with a 20 s on and 15 s off 
cycle. The crude protein was obtained by centrifugation at room temperature, 3000 x g, 
for 15 min. 
 
Purification of Rluc Fragments: The Hi-Trap copper chelating column precharged with 
CuSO4 was prepared by washing with 5 mL of distilled water to remove the 20% ethanol 
storage solution. The column was equilibrated with 5 mL of binding buffer (50 mM 
sodium phosphate, pH 8.0 buffer containing 300 mM NaCl) before adding the samples of 
crude Rluc fragments. The column was then washed with 20 mL of binding buffer 
followed by a 10 mL of wash buffer (50 mM sodium phosphate, pH 8.0 containing 300 
mM NaCl and 5 mM imidazole). The purified Rluc fragments were eluted with 2 mL of 
elution buffer (50 mM sodium phosphate, pH 8.0 containing 300 mM NaCl and 100 mM 
imidazole). The purity of eluted fractions was determined by SDS-PAGE (Appendix C). 
Protein concentration was determined via Bradford assay. A volume of 100 µL of each 
Rluc fragment was placed separately as well as mixed together into a microtiter plate, and 
the light intensity was measured after the addition of 0.5 µL of ctz (1 mg/mL).  
 
Labeling of Rluc fragments: The conjugations for both the C-terminal fragment and N-
terminal fragment consisted of a two step process. First, the crosslinker BM(PEO)2 and 
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the Rluc fragments were linked through the cysteine thiol moiety which is adjacent to the 
SGGGGS flexible linker present on the fragments, followed by addition of the thiol-
modified oligonucleotide probes (Figure 4.3). In order to conjugate the Rluc fragments to 
BM(PEO)2, the fragments’ disulfide bonds formed from the exposed cysteine residues 
were reduced by adding 10-fold mole excess of TCEP to the Rluc fragments, while 
stirring for 30 min at room temperature. Next, the BM(PEO)2 was added to the Rluc 
fragments in a two-fold mole excess, while stirring for 2 h at room temp. Before adding 
the thiol-modified oligonucleotide probes, the disulfide bonds between the probes were 
reduced with 40 mM TCEP for 30 min at 37oC. After reducing, the oligonucleotide 
probes were added dropwise to the stirring Rluc fragment-BM(PEO)2 solution. The final 
mole ratio of Rluc fragment: crosslinker: oligonucleotide probe was 1:2:5. Upon linking 
the oligonucleotide probe to the Rluc fragment, extensive dialysis against PBS buffer (50 
mM NaHPO4, 300 mM NaCl, pH 7.2) was performed to remove unconjugated linker and 
probe. It is important to note that there are four possible products after conjugation: 
unmodified Rluc fragment; an Rluc fragment dimer linked by the BM(PEO)2, an 
oligonucleotide dimer; and the correct Rluc fragment-oligonucleotide probe conjugate. 
Unreacted Rluc fragments and fragment dimers were not separated from labeled fragment 
since removal using dialysis will be a challenging task due to the small difference in 
molecular weight between oligo-labeled and unlabeled fragments. Additionally, since the 
fragments are inactive in isolation and cannot form functional Rluc by self-reassembly, 
non-conjugated Rluc fragments would not cause any interference or yield any 
background signal. The oligonucleotide dimers were separated in the dialysis step. 
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Figure 4.3 Split luciferase-DNA conjugation. A schematic representing the two-step Rluc 
fragment conjugation to the oligonucleotide probe in the presence of the crosslinker BM(PEO)2. 
The fragment is first conjugated to the crosslinker, and next the reduced oligonucleotide probe is 
added to allow conjugation through the free maleimide group. Reprinted with permission from 
Reference 90. Copyright 2009 American Chemical Society. 

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Hybridization Study: A 1 x 10-11 M concentration of Rluc N-terminal fragment probe 2 
conjugate and Rluc C-terminal fragment probe 1 conjugate was prepared in PBS buffer 
(100 mM sodium phosphate buffer containing 250 mM NaCl, 1 mM EDTA, and 0.1% 
BSA, pH 7.4). A volume of 100 µL of both fragment probe conjugates were mixed 
together and incubated at 37oC for 30 min. At the end of 30 min, the probe mixture was 
placed in a white, flat-bottom microtiter plate and 0.5 µL of coelenterazine (ctz) was 
added to the plate and luminescence measurement was performed with a 100 ms 
integration time. Control studies were performed using (1) buffer + ctz, (2) buffer + Rluc-
N terminal fragment probe 1 conjugate + ctz, (3) buffer + Rluc-C terminal fragment 
probe 2 conjugate + ctz. Next, different concentrations of two Rluc fragment probe 
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conjugates were mixed together in equimole amounts and incubated at 37oC for 30 min. 
Coelenterazine was added at the end of the incubation period and the luminescence 
intensity was measured.  
 
Effect of free probe 1: A mixture of Rluc-N-terminal fragment probe 2 conjugate and 
Rluc-C-terminal fragment probe 1 conjugate, and 100 µL of two different concentrations 
(17 µM, 66 µM) of free probe 1 was incubated at 37oC for 30 min in a microtiter plate. 
Next, 0.5 µL of ctz was added to the wells and luminescence measurement was 
performed. 
 
4.3 Results and Discussion 
The most critical issue in the success of protein reassembly from its split 
fragments is the selection of a cleavage site in the protein. Cleavage in regions inherent to 
interactions with the protein’s substrate or catalytic residues which are not recovered 
through protein complementation will render the protein reassembly non-detectable. 
Availability of the three-dimensional structure can aid in the design of the protein 
fragments. Other considerations in the design of successful protein reassembly include 
small protein size, monomeric structure, and simplicity of the assay system. Reassembly 
of split Renilla luciferase from its fragments, driven by the interactions between the 
proteins myoD and Id in vivo, has been demonstrated 141, although the fragments were not 
isolated or purified. On the basis of this work a cleavage site of Gly229-Lys230 was 
chosen to dissect Rluc. The X-ray crystal structure of a mutant of Rluc was solved 
recently 142, however, the cleavage site was selected on the basis of prior work performed 
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in detecting protein-protein interactions using the native Rluc. The X-ray crystal structure 
of the Rluc mutant shows that it has a classic α/β-hydrolase fold at its core and contains a 
catalytic triad made from Asp120-Glu144-His285. The cleavage site selected in our 
study, Gly229-Lys230, would be such that the residue Asp120 and Glu144 of the 
catalytic triad will be in the N-terminal fragment whereas His285 will be in the C-
terminal fragment (Figure 4.4). This suggests that although the substrate binding may 
occur in the N-terminal fragment, the catalytic triad is not completed until the two 
fragments come close for the generation of the bioluminescence signal. In the future, 
other cleavage sites could be evaluated on the basis of the X-ray crystal structure of Rluc. 
It would be interesting to cleave Rluc such that the triad is kept intact in one of the 
fragments while the substrate binding is disturbed in the absence of assembly of the two 
fragments. This type of fragmentation where the active site is maintained may reduce the 
overall time needed for reassembly of protein as observed in the case of split GFP work 
134
.  
Using the gene for native Rluc from the plasmid phRL-CMV as the template, 
primers were designed to introduce a non-cleavable 6-histidine tag to allow purification 
of the Rluc fragments as well as codons for a flexible amino acid linker and a cysteine 
residue for nucleic acid conjugation. The Rluc N-terminal fragment was constructed by 
introducing two stop codons after the amino acid Gly229 using site-directed mutagenesis. 
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Figure 4.4 Rluc crystal structure. The X-ray crystal structure of Rluc8 a mutant of Rluc showing 
the three catalytic triads. The N-terminal Rluc fragment region is shown in grey and the C-
terminal Rluc fragment region is shown in black. Reprinted with permission from Reference 90. 
Copyright 2009 American Chemical Society. 
 
 
Similarly, primers were designed to obtain the gene sequence of the C-terminal fragment 
of Rluc (amino acid 230-311) with a unique cysteine near its N-terminus. Rluc fragments 
were expressed in E. coli cells and purified using a copper-immobilized Hi-Trap column. 
The purity of the two fragments was verified using SDS-PAGE and Coomassie staining 
(Appendix C). The SDS-PAGE shows that the two fragments, the N-terminal fragment 
(~30 kDa) and the C-terminal fragment (~16 kDa) were purified efficiently. The 
luminescence activity of the individual Rluc fragments (1 nmole) was monitored by 
Rluc N-terminal 
fragment
Rluc C-terminal
fragment
Asp120 Glu144
His285
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adding the substrate coelenterazine. As expected, no luminescence signal was observed in 
the presence of substrate, indicating the inability of fragments to process the 
coelenterazine (Figure 4.5). Next, the two fragments (1 nmole each) without the probe 
attached were mixed together followed by the addition of coelenterazine to check for any 
nonspecific binding between the fragments in the absence of oligonucleotide probes. The 
mixing of the two fragments did not result in the generation of any bioluminescence 
signal indicating that spontaneous reassembly between Rluc fragments does not occur 
(Figure 4.5).  
 
 
Figure 4.5 Bar graph showing the luminescence activity obtained in control and samples. The 
data arebased on an average response of three samples ± the standard deviation. The inset shows 
a plot of luminescence activity obtained after mixing different moles of the probe 1-Rluc N-
terminal fragment conjugate and probe 2-Rluc C-terminal fragment conjugates and adding 
coelenterazine. The data are based on an average response of three samples ± the standard 
deviation. Reprinted with permission from Reference 90. Copyright 2009 American Chemical 
Society.

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Thiol-modified oligonucleotide probes were conjugated to the split Rluc fragment 
using maleimide-sulfhydryl chemistry through the homobifunctional crosslinker 
BM(PEO)2 (1,8-bis-Maleimidotriethylene glycol). The Rluc N-terminal fragment 
contains three cysteine residues with limited accessibility. Therefore, it is hypothesized 
that a cysteine introduced at the C-terminus during the construction of the fragment will 
be the major target site for oligonucleotide conjugation through the thiol moiety. The 
Rluc C-terminal fragment does not contain a cysteine residue, therefore, the cysteine 
introduced near the N-terminus of the C-terminal fragment via site-directed mutagenesis 
was targeted for the oligonucleotide conjugation. In order to perform the conjugation 
Rluc fragments were first reduced using tricholroethyl phospine, TCEP. Rluc fragments 
were then reacted with BM(PEO)2 using the manufacturer’s protocol in a 1:2 ratio of 
fragments to linker. Both oligonucleotide probes (Probe 1- 5’-SH-
TAGCTTATCAGACTGATGTTGA3’ and Probe 2-
5’TCAACATCAGTCTGATAAGCTA-SH-3’) were reduced using 40 mM TCEP at 
37°C and were added at a 5 times mole excess to the Rluc-BM(PEO)2 conjugate. Probe 2 
was conjugated to the N-terminal fragment and probe 1 was fused to the C-terminal 
fragment. Unreacted probes and crosslinker were then separated using dialysis in sodium 
phosphate buffer (50 mM sodium phosphate, pH 7.2 containing 300 mM NaCl). Removal 
of any unreacted Rluc fragments using dialysis is not possible due to the larger size of the 
fragments. However this should not be problematic for our study because the fragments 
either alone or mixed together do not yield any luminescence signal in the presence of 
coelenterazine.  
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Initially, a control study was performed to determine any background signal from 
fragment-probe conjugates. The bioluminescence measurements were performed by 
adding coelenterazine to Rluc-N-terminal fragment-probe 2 and to Rluc-C-terminal 
fragment-probe 1 separately. The luminescence signal obtained using probe-fragment 
conjugates was comparable to that obtained using buffer mixed with coelenterazine. 
Next, nanomoles of each of the two probe-fragment conjugates were mixed together at 
37oC for 30 min and bioluminescence intensity was measured after the addition of 
coelenterazine. Figure 4.5 depicts a bar graph of luminescence intensity obtained upon 
mixing the two complementary probe-fragments and the intensity obtained in the control 
study. The control resulted in a minimal background luminescence representative of the 
luminescnece of coelenterazine alone. In comparison, a strong bioluminescence signal 
was observed upon formation of an active Rluc driven through probe hybridization. In 
another study, various concentrations of probe-Rluc fragment conjugates were mixed and 
bioluminescence signal measured after incubation. A linear increase in luminescence 
with increasing concentrations of the two probe-fragment conjugates was obtained 
(Figure 4.5 inset). A detection limit of 5 fmoles (2.5 x 10-11 M) of probe-Rluc fragment 
conjugates. This detection limit was calculated corresponding to the signal obtained using 
the formula: signal of the blank + 3 times the standard deviation of the reagent blank. In a 
study performed using GFP as the reporter for fragment reassembly driven through DNA 
hybridization, the concentrations of probe-GFP fragment conjugates employed were 200 
nM 134. Results indicate that oligonucleotide probe hybridization using Rluc reassembly 
was detected approximately 4 orders of magnitude lower than that with split GFP.  
78 

A bioluminescence emission profile of the reassembled Rluc compared to the 
native Rluc (Figure 4.6) was obtained. The reassembled protein showed an emission 
maximum of 495 nm, while the native Rluc showed a 485 nm emission peak. This red 
shift of reassembled protein vs. native protein has been observed previously with GFP 134. 
It is thought that the shift in emission wavelength may be explained by the change in 
proximity of the amino acids around the chromophore compared to the native Rluc, as 
well as the presence of the negatively charged DNA molecules driving the reassembly. 
 

Figure 4.6 Luminescence emission scan of native Rluc and reassembled Rluc. Bioluminescence 
emission scan obtained using a Cary Eclipse fluorometer of reassembled Rluc (solid line) and 
intact Rluc (dotted line) after adding coelenterazine. Reprinted with permission from Reference 
90. Copyright 2009 American Chemical Society. 

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Next, the potential application of hybridization-driven Rluc reassembly for target 
miRNA detection was studied using a synthetic DNA oligonucleotide as a target, 
mimicking the microRNA miR21. This was evaluated by examining whether the 
fragment reassembly driven through oligonucleotide hybridization can be competitively 
inhibited by a free complementary probe. When an excess of free oligonucleotide probe 
(13.2 nmoles) (5’-TAGCTTATCAGACTGATGTTGA-3’) was added to the reassembled 
Rluc fragment-probe complex (1 nmole) a reduction in the bioluminescence signal was 
observed. Approximately 45% reduction in the bioluminescence intensity in the presence 
of free probe compared to the control without the free probe was observed. Although 
excess free probe was used, complete quenching of the bioluminescence was not 
observed. A possible reason for this is when the free probe is added to the fragment-probe 
hybridized complex, a higher temperature than 37oC may be needed to separate 
hybridized strands. A similar phenomenon was observed in the study performed using 
GFP split fragments in oligonucleotide hybridization 134. To further validate this result, 
when 3.4 nmoles of free probe was added to the probe-directed reassembled Rluc (1 
nmole each), a 25% reduction in the bioluminescence intensity was observed. This result 
indicates that the free probe can prevent DNA-directed reassembly of Rluc in a 
concentration-dependent manner.  
Ideally, a competitive assay can be performed such that the free probe is allowed 
to hybridize with the complementary probe-Rluc fragment followed by the addition of the 
second probe-Rluc fragment. An alternative method would be to simultaneously mix 
probe-fragment conjugates and the free probe. Another strategy to perform target nucleic 
acid quantitation can be based on designing the probes such that they bind adjacently to 
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the target. Here, the Rluc fragments can be conjugated to the probes and directly added to 
the target to be detected. This would allow reassembly of fragments and generation of 
active Rluc in the presence of the target, yielding an increase in the signal rather than a 
decrease.  
Finally, the reassembly of probe-Rluc fragments was performed in a cellular 
extract to evaluate whether the Rluc assembly strategy would work in a more complex 
matrix. Another objective that was fulfilled by this experiment was to evaluate whether 
any nonspecific nucleic acid present in the sample will interfere with the hybridization of 
probes and hence the subsequent reassembly of Rluc fragments. For this study, E. coli 
strain ER2566 cell extract was utilized. To obtain the extract, sonication was performed, 
which also is employed for genomic DNA isolation 143. After sonicating the cells in PBS 
buffer, 1 nmole of the probe 2-N-terminal Rluc fragment and probe 1-C-terminal Rluc 
fragment were mixed with the cell extract and hybridized. The luminescence intensity 
obtained was comparable to that obtained in the in vitro study (Figure 4.7). A comparison 
of the light intensity in the buffer matrix and in the E. coli cell matrix showed an 
approximately 4.1% decrease from buffer matrix to cell extract matrix. Therefore, 
reassembly of Rluc driven through DNA hybridization is not significantly affected by the 
cell extract matrix. 
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Figure 4.7 Reassembled Rluc luminescence intensity in buffer vs. cell extract. Luminescence 
intensity obtained after adding coelenterazine to the samples containing probe-fragment 
conjugates in buffer and E. coli cell extract. The data are based on an average response of three 
samples ± the standard deviation. Reprinted with permission from Reference 90. Copyright 2009 
American Chemical Society. 
 
 
4.4 Conclusions
This work demonstrates that Rluc reassembly can be performed in vitro driven 
through oligonucleotide hybridization. The detection limit for Rluc reassembly was 5 
fmoles (2.5 x 10-11 M) of probe-Rluc fragment conjugates, which is approximately 4 
orders of magnitude lower than that reported using probe-GFP fragment conjugates. 
These studies also show that the reassembly can be inhibited in the presence of a 
complementary oligonucleotide mimicking the sequence of the microRNA miR-21, 
indicating that this strategy can be useful in the quantitative detection of target miRNA. 
The bioluminescence emission, small size, and monomeric structure make Rluc an 
efficient label for the development of complementation assays. Furthermore, the method 
developed offers the advantage of parallel analysis in a 96-well microplate format, 
82 

allowing for high throughput capabilities. Hybridization in a complex cell extract matrix 
did not significantly affect hybridization as evidenced by no significant change in light 
output upon addition of coelenterazine. 
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CHAPTER 5: FLUORESCENCE-BASED MICRORNA DETECTION 



5.1 Introduction 
The three methods employing Renilla luciferase described previously, while 
powerful in their applications to miRNA detection, have only reported the detection of a 
single target, miR21.  It is of interest to expand the miRNA detection methods available 
to include analysis of multiple miRNAs.  A simple method to detect more than one 
miRNA target can involve the incorporation of fluorescent dyes.  Fluorescent dyes, when 
attached to nucleic acids, can be effective labels for the detection of hybridization 144-146.  
Fluorescent dyes, approximately 0.5 nm in diameter, are advantageous to bioluminescent 
proteins, fluorescent proteins, and quantum dots due to their small size 147. Quantum dots 
vary in size from 2-10 nm in diameter, while luminescent proteins are approximately 5 
nm in diameter 148.  Fluorescent dyes are also commercially available with multiple 
functional groups, including succinimidyl esters, iodoacetamides, and maleimides, 
allowing for ease of conjugation to thiol and amine-modified oligonucleotides.  
Fluorescent dyes also have the advantage of a wide array of excitation and emission 
wavelengths, and can be paired with numerous fluorescent molecules for FRET-based 
assays 149, 150.  Due to their small size, brightness, variety of excitation/emission 
wavelengths, and ability to conjugate to nucleic acids, fluorophores will be employed as a 
label to detect hybridization of miRNA oligonucleotide targets in a quantitative manner.  
84 

As a proof of concept, two synthetic oligonucleotides mimicking microRNAs miR155 
and miR103, were employed to demonstrate that more than one miRNA can be detected 
in the same assay, in a solution-phase format.  In addition to reporting the detection of 
dual targets in a single assay, it is also important to employ hybridization conditions 
which result in maximal specificity (the ability to differentiate between single nucleotide 
mismatches) and sensitivity.  Therefore, hybridization optimization is discussed in the 
following chapter as well.  
Several microRNAs have been implicated in pancreatic cancer. Two of them, 
miR155 and miR103, are the focus of this chapter. It has been found that upregulation of 
miR103 and the downregulation of miR155 can differentiate pancreatic tumor cells from 
normal pancreatic cells 151, 152. To detect the miRNAs, two sets of oligonucleotide probes 
were designed, one set containing a fluorophore (miR155-T1 and miR103-T2), and the 
other set consisting of a complementary probe containing a quencher (miR155-CT1 and 
miR103-CT2). In the absence of target, the two complementary probes hybridize, 
resulting in a quenching of fluorescence upon excitation. In the presence of target, the 
target hybridizes with the quencher probe, inhibiting hybridization between the quencher-
probe and fluorophore-probe (Figure 5.1). Therefore, as target concentration increases, 
the fluorescence increases until saturation is reached. 
This assay design, although similar to a molecular beacon (MB) with the 
fluorophore and quencher, is advantageous compared to the MB. MBs contain a short 
stem of approximately 6 base pairs, and a single-stranded loop containing 15-40 bases 153. 
This short stem can often separate, resulting in inadequate quenching of the fluorophore. 
With the current assay design, the quencher and fluorophore probes are 22 and 23 
nucleotides for the miR103 and miR155, respectively. These longer length probes can
prevent separation of the two probes through increasing the melting temperature of the 
hybridization complex, resulting in less background signal than molecular beacons. 
While the concept of two complementary oligonucleotide probes containing a 
fluorophore and quencher has been employed previously for hybridization studies 
involving truncated probe sequences
probe pairs have not been utilized in this manner for microRNA detection. 
Figure 5.1 Fluorophore/quencher
fluorophore-probe and quencher
upon excitation. B) In the presence of target, the quencher
inhibiting the fluorophore-
increase in fluorescence upon excitation.
 
154, 155
, fluorophore and quencher oligonucleotide 
-based miRNA detection assay. A) In the absence of target, the 
-probe hybridize, resulting in a quenching of the fluorescence 
-probe hybridizes with the target, 
probe from hybridizing with the quencher-probe, resulting in an 
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Quantum dots, although having desirable properties including enhanced resistance 
to photobleaching, face problems with toxicity due to leakage from their metal core 147, 
156, 157
. The small size of the fluorophores also presents an advantage over the use of 
quantum dots as well as fluorescent and bioluminescent proteins. This assay design is 
also desirable due to its solution-phase capability. Another important advantage to the 
detection method described here is its ability to detect two targets in the same solution. 
Simply selecting the fluorophores such that non-specific emission does not occur due to 
spectral overlap between the two fluorophores will allow for the dual-detection 
capabilities. Here, a dual miRNA target detection method is reported, while also 
displaying target specificity and compatibility in more complex matrices. 
 
5.2 Materials and Methods 
Reagents: Sodium chloride, sodium tetraborate, boric acid, sodium phosphate, and white 
flat-bottom 96 well plates were all obtained from Thermofisher Scientific (Pittsburgh, 
PA). E. coli strain ER2566 was obtained from New England Biolabs (Ipswich, MA). 
Modified oligonucleotide probes were all obtained from Integrated DNA Technologies 
(Iowa City, Iowa). Synthetic DNA targets were obtained from Operon Biotechnologies 
(Huntsville, AL). Synthetic RNA targets were obtained from Invitrogen (Carlsbad, CA). 
All buffers were made with ultrapure milli-Q water (18 MΩ). Diethyl pyrocarbonate 
(DEPC) was purchased from Acros Organics (Geel, Belgium). RNAsin RNAse inhibitor 
was purchased from Promega (Madison, WI). Fluroescence measurements were 
performed on a Varian Cary Eclipse fluorescence spectrophotometer with a 
photomultiplier tube voltage of 600 V. 
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Oligonucleotide Probe Design: DNA oligonucleotide probes were designed depending 
on their target. Each oligonucleotide probe was synthesized either with a fluorophore at 
the 5’ end or a quencher at the 3’end. Fluorophore-probes were designed to be the same 
sequence as target, and quencher-probes were designed to be complementary to their 
respective targets. Oligonucleotide probes and their targets are seen in Table 5.1.  Both 
DNA and RNA targets were designed based on the hsa-miRNA sequences of miR155 
and miR103. The miR155 T1 and CT1 probes were modified with 6-carboxy fluorescein 
and Iowa Black FQ quencher, respectively. The miR103 T2 and CT2 probes were 
modified with Texas Red and Iowa Black RQ quencher, respectively.  
 
Table 5.1 Fluorophore/quencher oligonucleotide probe design 
Strand Name Sequence 
FAM-T1 miR155 5’-FAM-TTAATGCTAATCGTGATAGGGGT-3’ 
IowaBlack-CT1 miR155 5’-ACCCCTATCACGATTAGCATTAA-IowaBlack-3’ 
miR155 Target 5’-UUAAUGCUAAUCGUGAUAGGGGU-3’ 
TEX615-T1 miR103 5'-tex615-AGCAGCATTGTACAGGGCTATGA-3' 
IowaBlack-CT1 miR103 5'-TCATAGCCCTGTACAATGCTGCT-IowaBlack-3' 
miR103 Target 5'-AGCAGCAUUGUACAGGGCUAUGA-3' 
 
 
Optimization of probe hybridization: Hybridization time was optimized. Hybridization 
times between 10 min and 60 min were performed for detection of synthetic DNA 
mimicking miR155. Well plates were covered with parafilm and aluminum foil to 
prevent evaporation and quenching of the fluorophores due to light exposure. The 
hybridization order of quencher-CT1 + target, followed by a five minute wait time, and 
addition of fluorophore-T1 probe was employed for the time and temperature 
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hybridization optimization. Varying amounts of miR155 DNA target were employed 
(0.1-60 pmoles), with 20 pmoles of each fluorophore-probe and quencher-probe. 
 
Assay Specificity: To measure the specificity of the assay, one, two and three nucleotide 
mismatch target DNA oligonucleotides were designed for detection of miR155. 
Mismatches were selected at three different locations on the oligonucleotide. The 
sequences of the mismatch target DNA can be seen in Table 5.2, with nucleotide 
mismatches displayed as lowercase with red font. The hybridization buffer of 10 mM 
borate pH 7.4 was employed for all optimization assays. Equimole amounts (20 pmoles) 
of miR155-T1 and miR155-CT1 and increasing amounts of target (1 pmole-60 pmoles) 
were mixed. Hybridization took place for 30 minutes at room temperature. To optimize 
hybridization temperature, the one, two, and three nucleotide mismatch targets were 
hybridized in 10 mM borate buffer at 50oC, 42oC, 37oC, and room temperature. Triplicate 
samples were performed for each data point.  
 
Table 5.2 miR155 DNA target mismatch sequences 
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DNA target detection: Both the miR155 and miR103 DNA targets were detected both 
independently and simultaneously in 10 mM borate buffer pH 7.4. Equimole amounts (20 
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pmoles) of fluorophore-probe and quencher-probe were employed, along with varying 
amounts of target (0.1 pmoles-60 pmoles). For the miR103 DNA target detection 
excitation and emission wavelengths of 596 nm and 613 nm, respectively, were 
employed. For dual detection, multi-wavelength mode was utilized on the fluorescence 
spectrophotometer. Samples were prepared by mixing target and quencher-probe, 
hybridizing for 5 minutes at room temperature, followed by addition of fluorophore-
probe and hybridization for 30 min at 42oC. Triplicate samples were prepared for each 
data point. Reagent blanks for both the miR155 and miR103 DNA target detection were 
determined by measuring the fluorescence of the fluorophore-probe and quencher-probe 
with no target present, once hybridization reached equilibrium. New reagent blanks were 
performed for each assay. 
 
Complex matrix hybridization: In order to employ this method in more complex 
matrices, mouse serum and cellular extract from E. coli ER2566 cells was utilized. For 
the mouse serum, 25% serum, 75% buffer mixture was employed for the data collection. 
E. coli extract was prepared by growing E. coli ER2566 cells overnight, followed by 
resuspension in 10 mM borate buffer pH 7.4 and sonication to open the ER2566 cells. 
Cells were pelleted, and the supernatant was employed further for the assay. Samples 
were prepared by mixing target and quencher-probe, hybridizing for 5 minutes, followed 
by addition of fluorophore-probe, mixing, and taking the measurements 30 min after 
hybridization at 37oC. Total sample volumes were 150 µL.  Each sample was performed 
in triplicate. Concentration of target, fluorophore-probe and quencher-probe were 
identical to those utilized for the DNA target detection in borate buffer.  
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RNA target detection: To apply the assay to microRNA detection, synthetic microRNAs 
were employed. The assays performed for the RNA detection were all performed in 
nuclease-free water. To make the nuclease-free water, DEPC was added to 10 mM borate 
buffer, followed by incubation at 37oC, and autoclaving to deactivate free DEPC. RNA 
detection was performed in multiple matrices, as with the DNA detection. Matrices 
utilized were buffer, cell extract, and serum. Both single probe detection and dual probe 
detection were performed as with the DNA detection. Equimoles of quencher-probe and 
fluorophore-probe (20 pmoles) were utilized, along with varying amounts of RNA target 
(0.1 pmoles-60 pmoles). Synthetic RNA detection in serum required addition of RNAsin 
RNAse inhibitor to the serum. To prepare the RNAsin-treated serum, 2.5 µL of RNAsin 
per 37.5 µL of serum was added, followed by incubation for three hours at 37oC. All 
samples were performed in triplicate. 
 
5.3 Results and Discussion 
MicroRNA detection is vital to the understanding of cancer and disease 
progression. In order to develop a method for miRNA detection, a solution-phase 
approach has been utilized based on the design of fluorophore and quencher-labeled 
DNA oligonucleotide probes. Both probes were designed complementary to one another, 
with the fluorophore-probe (T1 or T2) consisting of the same nucleotide sequence as the 
target. Upon addition of target, quencher-probe and target hybridize. This prevents the 
fluorophore-probe from hybridizing to the quencher-probe, resulting in an increase in 
fluorescence.  
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In order to employ a method which is capable of detecting dual microRNAs in 
solution, fluorophores were chosen which were spectrally distinct, and would not result in 
cross excitation. With this in mind, FAM (6-carboxyfluorescein) fluorophore and TEX 
615 (Texas Red) were chosen. FAM has a 495 nm excitation and a 520 nm emission 
wavelength, while TEX 615 has a 596 nm excitation and a 613 nm emission wavelength. 
These two fluorophores were examined for cross-excitation. It was found that 613 nm 
emission was insignificant with an excitation of 495 nm, and 520 nm emission was not 
detectable with an excitation of 596 nm. To effectively quench the fluorophores, 
quenchers were chosen based on manufacturer’s recommendations (IowaBlackFQ for the 
FAM, and IowaBlackRQ for the TEX615). The order of reagents employed was 
quencher-probe + target, followed by addition of fluorophore-probe. When adding the 
fluorophore-probe and quencher-probe, followed by picomole amounts of target, the 
target is unlikely to displace the fluorophore-probe from the quencher-probe, resulting in 
quenching of the FAM fluorescence. In order for target to displace the fluorophore-probe, 
a truncated fluorophore-probe or quencher-probe can be designed with a sticky end 154, 
155; however, this method increases hybridization time due to the complex kinetics 
involved in initial hybridization and strand displacement, which is caused by the 
competing reaction of rehybridization of the displaced probe. The sequence of 
fluorophore-T1 probe + quencher-CT1 probe, followed by addition of target could be 
accomplished with the addition of an extremely large excess of target, as observed with 
the split luciferase assay, although it is optimal to detect lower amounts of target.  
The buffer chosen for hybridization was 10 mM Sodium tetraborate buffer pH 
7.4. A low buffer capacity buffer was chosen due to its low sodium concentration. 
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Sodium chloride was also not added to the hybridization buffer, as this may decrease 
hybridization stringency. The presence of sodium chloride minimizes charge repulsion 
among the negatively charged phosphate backbone of the hybridized complex, further 
stabilizing mismatches. Therefore, the buffer should not contain any sodium chloride in 
order to increase hybridization stringency. The hybridization time performed for the 
assay was determined to be 30 minutes.  At all hybridization temperatures (room 
temperature, 37oC, 42oC, and 50oC), the fluorescence intensity had leveled off by 30 
minutes.   
The placement of nucleotide mismatches is very important when studying the 
specificity of a hybridization assay. Each of the three mismatches shown in Table 5.2 was 
chosen carefully based on its neighboring bases. The first mismatch is flanked on the 5’ 
side by 5’-CG-3’, which according to the nearest neighbor model of melting temperature 
determination, will stabilize a mismatch duplex the greatest of any two base combination 
(∆Ho=11.9 kcal/mole) 158. Therefore, if the assay was capable of differentiating the single 
mismatch target, it should be capable of differentiating between miRNAs differing in one 
nucleotide, such as the let-7 family of miRNAs. The second nucleotide mismatch is 
flanked on the 5’ side by 5’-GC-3’, which, compared to the ten possible two base 
combinations, has the second highest enthalpy (∆Ho=11.1 kcal/mole) 158. Taken together, 
the combination of these two mismatches and their placement, will present difficulties in 
terms of specificity. The final mismatch is flanked at the 5’ by TT, which is does not 
possess the stabilizing effect that 5’-GC-3’ will have (∆Ho=9.1 kcal/mole); however, 
placing the mismatch very near the end of the probe sequence also presents difficulties in 
specificity, simply because nearly the entire length of the quencher-probe can still 
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hybridize with the target, resulting in an increase in fluorescence intensity. Based on this 
information, when designing mismatches, it is crucial to examine the bases flanking the 
mismatch placement. 
Hybridization temperature was optimized by monitoring nucleotide specificity 
and varying the temperature in 10 mM Borate buffer pH 7.4 (Figure 5.2). From the data, 
it is evident that 42oC hybridization is optimal, due to the enhanced specificity compared 
to the other hybridization temperatures (Figure 5.2C). The 42oC hybridization still 
possesses high signal intensities for the perfect match target. The two nucleotide 
mismatch target fluorescence intensity is baseline, along with the three nucleotide 
mismatch target (data not shown). The one nucleotide mismatch target still hybridizes 
non-specifically with the CT1 probe; however, hybridization efficiency is greatly reduced 
compared to room temperature hybridization (Figure 5.2A). At 50oC, fluorescence 
intensity of the fluorescein was greatly reduced due to the instability of the fluorophore at 
high temperatures (Figure 5.2D). The 37oC hybridization temperature is more stringent; 
however, this method only selects for the three nucleotide mismatch target, with the two 
nucleotide mismatch target still hybridizing with the quencher-probe (Figure 5.2B). The 
room temperature hybridization does not allow for discrimination of even the three 
nucleotide mismatch. Therefore, the 42oC hybridization temperature in 10 mM borate 
buffer pH 7.4 was the optimal hybridization buffer for target specificity. The results of 
the temperature study are indicative of the importance of the melting temperature of the 
duplex. For the DNA duplex, the miR155 DNA oligonucleotide has a melting 
temperature of 48oC according to the following equation, where [Na+] is the sodium 
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concentration and G+C represents the number of guanine and cytosine bases in the 
oligonucleotide.  
 
Tm = 81.6 + 16.6 x log[Na+] + (41 x G+C / oligonucleotide length) – (500 / oligo length) 
 
It is important to perform hybridization at least 5 degrees below the melting temperature 
in order to allow for annealing of the two nucleic acid probes. At a temperature greater 
than the melting temperature, the quencher probe and fluorophore probe should all be 
separate, thus resulting in a nonspecific increase in signal. The studies performed show 
the opposite. The reasoning behind this is the thermal instability of the fluorescein label.  
Calibration curves were obtained for the DNA targets of both the miR155 and 
miR103 to determine the detection limit of each. DNA targets were chosen first to 
evaluate the viability of the assay for the detection of RNA sequences. Hybridization was 
performed at 42oC for 30 minutes in 10 mM Borate buffer pH 7.4 (Figure 5.3A). The 
limit of detection, calculated from the equation SLOD=SBlank + 3*s, where SBlank is the 
signal of the reagent blank and s is the standard deviation of the reagent blank, was found 
to be 7.02 pmoles (46.8 nM) and 12.1 pmoles (80.8 nM) for the miR155 and miR103 
DNA targets, respectively. Hybridization was also performed at 37oC (Figure 5.3B) and 
room temperature (Figure 5.3C) as a comparison. The detection limits obtained for 
miR155 and miR103 DNA targets at room temperature hybridization were 1.81 pmoles 
(12.1 nM) and 0.280 pmoles (1.87 nM), respectively. For 37oC hybridization, detection 
limits for miR155 and miR103 DNA detection were 2.90 pmoles (19.4 nM) and 4.36 
pmoles (29.1 nM), respectively. The detection limits become gradually less favorable at 
higher temperatures. This result is most likely due to the fact th
stringency, lower concentration targets
Also, it should be noted that the fluorescence intensity decreased from lower temperature 
to higher temperature hybridization, owed to the instabilit
temperatures. Therefore, when optimizing 
the detection limit of the assay 
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quencher-probe, resulting in inefficiency of the quencher due to the inability of the 
fluorophore-probe and quencher-probe to hybridize. The result of this was seen with an 
increase in fluorescence upon excitation, even in the blank. In order to combat this, 
cellular extract was heated to deactivate the DNAses, and 2 mM EDTA was added as 
well. The inactivation of the DNAses through these two steps allowed the assay to be 
compatible in the cellular extract. The detection limits of miR155 DNA target and 
miR103 DNA target in the cellular matrix were calculated to be 3.58 pmoles (23.8 nM) 
and 11.8 pmoles (79.0 nM), respectively. While the optimal hybridization temperature for 
the miR155 target was 42oC, even with the pretreatment of the cell extract, performing 
the hybridization at this temperature gave poor results, likely due to heightened nuclease 
activity. Therefore, the lower temperature of 37oC was employed for hybridization. 
In order to perform the assay in serum, first the optimal serum concentration was 
determined by diluting the serum samples with 10 mM borate buffer, and adding 
miR155-T1 probe to the solution. Concentrations varied from 100% serum to 0% serum 
at 25% intervals. It was found that 100% serum completely masks the fluorescence of the 
FAM fluorophore. As the serum concentration decreases, the FAM fluorescence intensity 
increases. A serum concentration of 25% was chosen for the assays. For the dual DNA 
target detection in serum samples, the detection limits were calculated to be 8.89 pmoles 
(59.3 nM) and 8.38 pmoles (55.9 nM) for the miR155 and miR103 DNA targets, 
respectively (Figure 5.4B).  
Figure 5.4 miR155 and miR103 dual DNA target detection in cell extract and serum. 
response curve in E. coli ER2566 cell extract 37
serum. 
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To apply this assay to the detection of miRNA, synth
Both miR155 and miR103 RNAs were detected simultaneously in solution. One of the 
challenges with studying RNAs is the presence of RNAses, which can rapidly degrade 
RNAs. Therefore, nuclease
detection assays. Dual-probe detection was first performed in solution. The RNA 
detection resulted in detection limits of 6.03 pmoles (40.2 nM) for the miR155 target, and 
17.2 pmoles (115 nM) for the miR103 target 
targets, the miR155 detection limits were quite similar; however, the miR103 differed 
substantially, which may be due to trace levels of RNAses in the buffers.
compatibility of the synthetic miRNA detection in cellular extract was 
with the DNA target detection, the cellular extract was treated before use by heating to 
90oC for 5 min and adding EDTA. Observed detection limits for miR155 and miR103 
were 6.78 pmoles (45.2 nM) and 29.7 pmoles (198 nM), respectively 
slope of the calibration curves for the miR155 and miR103 were quite different, however. 
oC hybridization. B) Dose-response curve in 25% 
etic RNAs were 
-free DEPC-treated buffers were employed in all RNA 
(Figure 5.5A). Compared to the DNA 
tested as well. As 
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The miR155 displayed the same fluorescence intensity profile that the DNA target did, 
while the miR103 intensities were quite low compared to the DNA. To determine 
whether the received stock RNA oligo was already degraded, the concentration of 
miR103 RNA was tested along with imaging the RNA on an agarose gel. Both were 
validated in the presence of the RNA. While the assay was compatible in cellular extract 
for RNA detection, the RNAs immediately degraded in the presence of serum, resulting 
in a rapid decrease in fluorescence. Attempts to heat the serum and add EDTA did not 
improve the detection. It was therefore necessary to treat the serum with an RNAse 
inhibitor prior to addition of synthetic RNA. RNAsin is a solution containing a 56 kDa 
protein which functions by binding to RNAses in a 1:1 ratio, inhibiting RNAse activity. 
RNAsin was added to the serum in a 1:10 ratio of inhibitor (64 U/ µL) to serum, followed 
by incubation for 3 h at 37oC and normal assay preparation. The addition of the RNAsin 
greatly increased RNA stability for the miR103, displaying detection limits of 20.4 
pmoles (136 nM); however the miR155 still degraded (Figure 5.5C). It should be noted 
that naturally occurring miRNA is stable in serum compared to synthetic RNA 159. 
RNAsin is a solution containing a 56 kDa protein which functions by binding to RNAses 
in a 1:1 ratio, inhibiting RNAse activity. RNAsin was added to the serum in a 1:10 ratio 
of inhibitor (64 U/ µL) to serum, followed by incubation for 3 h at 37oC and normal assay 
preparation. The addition of the RNAsin greatly increased RNA stability for the miR103, 
displaying detection limits of 20.4 pmoles (136 nM); however the miR155 still degraded 
(Figure 5.5C). It should be noted that naturally occurring miRNA is stable in serum 
compared to synthetic RNA 159. This suggests that serum miRNAs must be protected 
from RNAses in a way that is not possible for synthetic RNA. The reason behind RNA 
protection in serum has been attributed to its packaging in vesicles
unprotected spiked RNA is highly unstable. Since microRNA has been found to be 
present in serum, this method could allow for microRNA detection directly in serum after 
concentration of the samples.
Figure 5.5 miR155 and miR103 
buffer 0.1%DEPC with 37o
37oC hybridization. C) Dual detection in 25% serum with 37
 
 
This method was capable of detecting dual target nucleic acid in a wide variety of 
matrices with detection limits in the nanomolar range with two nucleotide specificity. 
The specificity can be further optimized through the incorporation of LNAs in the CT1/
 
dual RNA target detection. A) Dual detection in 10 mM Borate 
C hybridization. B) Dual detection in E. coli ER2566 cell extract with 
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or T1/2 probe sequences. Also, additives such as formamide may increase specificity to 
discriminate single nucleotide mismatches. This method was very rapid, performed in 
only 30 minutes. Dual targets were able to be detected simultaneously through measuring 
the fluorescence intensities of the two fluorophore emission wavelengths. This method 
also displayed the ability to detect synthetic microRNA in the nanomolar range. Although 
the synthetic RNA is not stable in untreated serum, addition of RNAse inhibitors to 
buffer allowed for miR103 target detection. Due to the fact that native serum miRNAs 
are stable, this method can be applied to the direct detection of miRNA in serum. This 
method represents a simple, rapid, sensitive detection method for the quantitation of dual 
microRNAs in solution, which can ultimately serve as a screening method for microRNA 
expression profiles.  
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CHAPTER 6: CONCLUSION 
 
6.1 Summary of Developed Methods 
With the recent implication of miRNA levels and their role in disease progression, 
it is extremely important to be able to detect this small, 18-24 nucleotide length RNA 
molecule. While multiple methods of miRNA detection have been developed previously, 
each method suffers at least one drawback, whether lacking specificity, sensitivity, a 
lengthy assay, or requiring expensive equipment. In order to overcome these drawbacks, 
three novel miRNA detection methods were developed based on employing Renilla 
luciferase as a label and also one method employing fluorophores as labels. All four 
methods are rapid, simple, and do not require highly expensive equipment. The following 
is a summary of each of the four detection methods, along with future directions which 
can be applied to expand these four methods’ utilitity to miRNA detection. A table 
summarizing the attributes and specifics of each of the four methods is found in this 
section (Table 6.1). 
First, a solid-phase miRNA detection method employing Renilla luciferase as a 
label was developed. The advantages of this assay are its application in a microplate 
format and thus high-throughput screening capability, along with its high sensitivity. This 
method produced a detection limit of synthetic miR21 RNA in phosphate buffered saline 
of 5 femtomoles (25 pM). This method was also applied to detection of real miR21 in 
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two mammalian cell lines. A drawback of this method is that it relies on a decrease in 
bioluminescence intensity upon increasing amounts of target, rather than an increase in 
bioluminescence intensity. Another drawback for this assay is that multiple wash steps to 
remove unbound oligonucleotide probes are required, thus increasing the total assay time. 
For this method, the total assay time after blocking the well-plate with bovine serum 
albumin was 90 minutes. Although the assay is 90 minutes in length, it is still 
advantageous over Northern blotting. It is advantageous to microarrays and qRT-PCR in 
terms of cost. 
To expand the utility of this miRNA detection method, and apply it to diagnostics, 
serum extract samples from patients with and without breast cancer have been collected 
and are being analyzed in the lab based on their miR21 expression levels. The solid-phase 
method is being employed to analyze the samples, and a modified Renilla luciferase 
protein containing eight mutations (RL8) is being employed which possesses enhanced 
light output compared to the native Renilla luciferase employed for the work in this 
dissertation 160. In the future, this method should be optimized to selectively detect 
perfect match target miRNA from single nucleotide mismatch RNA. 
Second, a BRET-based detection method was employed to detect a DNA 
oligonucleotide corresponding to miR21. The BRET donor was Rluc, while the BRET 
acceptor was a quantum dot. The advantages of this assay were that it can be performed 
in the solution-phase, and thus does not require the washing steps as with solid-phase 
assays. Also, this method is very rapid, with a total assay time of only 30 minutes. The 
BRET-based assay was shown to detect as little as 4 picomoles of target (20 nM). The 
disadvantages of this assay are that it also relies on a decrease in BRET signal (quantum 
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dot emission) upon increasing the amount of target present in the sample. Another 
disadvantage is the detection limit is not as desirable as with the solid-phase method. The 
reasoning behind this is that resonance energy transfer-based assays are not as sensitive 
as standard luminescence assays involving a single label. Smaller diameter quantum dots 
can be employed to combat this sensitivity issue in order to decrease the distance between 
donor and acceptor. Despite the drawback of limited sensitivity, the total assay time is a 
substantial advantage over the solid-phase assay. 
In the future, this method can be applied to the detection of the breast cancer 
patient sera samples that are being employed for the solid-phase assay. Along with the 
miR21 detection, probes can be employed along with spectrally distinct quantum dots, 
such that multiple miRNAs can be detected in a multiplex format.  
Third, a protein complementation-based detection method was employed for the 
analysis of a synthetic DNA oligonucleotide mimicking miR21 microRNA. This method 
was developed based on previous reports that proteins, when genetically engineered to 
form two inactive fragments, may reform an active enzyme when coming into close 
proximity with one another. As with the BRET-based method, an advantage of this 
method is that the total assay time is 30 minutes. Another advantage of this assay is that 
the background signal is insignificant, unlike the high background associated with 
fluorophore-based applications. A disadvantage of the assay is that in order to detect 
miRNA, a decrease in signal is observed.  
In the future, the split luciferase method should be employed to detect real 
miRNA samples such as the serum extract samples. Differing split sites should also be 
tested to determine if luminescence recovery increases compared to the current split site. 
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Also, the split luciferase method should be applied to the detection of larger, precursor 
miRNA, such that the oligonucleotides bound to the two fragments will hybridize 
adjacently to one another, resulting in an increase in signal upon target detection, rather 
than a decrease.  
Fourth, a fluorescence-based miRNA detection method was developed in which 
fluorophore-labeled oligonucleotides hybridize with quencher-labeled oligonucleotides in 
the absence of target. In the presence of target, however, the target hybridizes with the 
quencher-probe, thus preventing the fluorophore-probe from hybridizing with the 
quencher-probe. Therefore, in the presence of target, the fluorescence intensity will 
increase. This method was very rapid, with the ability to be performed in 30 minutes. 
Another advantage was the ability to detect dual targets in the same solution due to the 
incorporation of spectrally distinct fluorophores on separate oligonucleotide probe sets. 
The detection limit of this assay was approximately 2-80 nM for both independent and 
dual target detection. A limitation to this assay is that the detection limit is not as 
desirable as with the solid-phase method. Another limitation is the stability of the 
fluorophores at high temperatures. Hybridization temperatures above 50oC cannot be 
used due to a loss of fluorescence of the fluorophore. Despite the drawbacks, the total 
assay time, as with the other solution-phase assays developed, and also the need for only 
a fluorescence microplate reader, make the fluorophore/quencher method desirable for 
miRNA quantitation. In the future, this method should be applied to the detection of 
patient samples containing miR155 and miR103.  
Comparing each of the four detection methods, the solid-phase method is the most 
desirable for diagnostic applications due to its high sensitivity and low cost. The 
106 

remaining three methods should be tested for their diagnostic value in the analysis of 
patient samples. 
 
Table 6.1 Description of miRNA detection methods developed in this dissertation 
Detection 
Method Description 
Detection 
Limit 
Solid-phase 
Oligonucleotide probe with the same sequence as target miR21 is labeled 
with Rluc. Target and Rluc-DNA conjugate compete to hybridize with a 
biotinylated capture probe. Rluc signal decreases upon increasing 
concentration 
5 fmoles 
(25 pM)  
BRET-based 
Solution-phase method where oligonucleotide probe with the same sequence 
as target is labeled with Rluc. Oligo probe complementary to target is labeled 
with QD. In absence of target, BRET from Rluc to QD occurs. In presence of 
target, less QD-probe and Rluc-probe will hybridize, resulting in less energy 
transfer between the Rluc and QD. 
4 pmoles 
(20 nM) 
Protein 
reassembly-
based 
Solution-phase method where oligonucleotide probe with the same sequence 
as target is labeled with C-terminal fragment. An oligo probe with the 
complementary sequence to target is labeled with N-terminal fragment. In 
absence of target, reassembly of Rluc occurs, resulting in generation of 
luminescence upon addition of coelenterazine. In the presence of target, less 
reassembly occurs, resulting in a decrease in luminescence intensity upon 
addition of coelenterazine. 
3.4 
nmoles 
(17 µM) 
Fluorophore/ 
quencher-
based 
Solution-phase method where oligo probe with the same sequence as target is 
labeled with fluorophore. An oligo probe with a complementary sequence to 
the target is labeled with a quencher probe. In the absence of target, the 
fluorophore-probe and quencher-probe hybridize, resulting in a quenching of 
fluorescence upon excitation. In the presence of target, less fluorophore-probe 
hybridizes with quencher-probe, resulting in an increase in fluorescence 
intensity upon excitation. 
~0.3-10 
pmoles 
(~2-80 
nM) 
 
 
6.2 Comparison of Developed miRNA Detection Methods to Prior Methods 
Comparing the developed methods in this dissertation to the methods outlined in 
the introduction, the detection limit of the solid-phase method rivals that of the new and 
emerging miRNA detection methods. What separates the solid-phase method in this work 
from the other methods is assay simplicity as well as assay cost. None of the prior 
methods have employed bioluminescent proteins which can be reproducibly produced, 
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thus lowering costs. On the basis of cost and simplicity, the solid-phase method is an 
improvement over all previous miRNA detection methods.  
The BRET-based method, while lacking in sensitivity, is superior to all the 
previous methods in that the total assay time is very rapid, and only a microplate reader is 
needed for detection. The BRET-based method is also superior to the electrochemical and 
optical methods in that multiplex detection can be performed, although not outlined in the 
work presented here. 
The protein reassembly-based method, like the BRET-based method, is inferior to 
the previous methods in terms of sensitivity. While lacking in sensitivity this method is 
very rapid, simple, and requires only a microplate reader for detection of target. This 
assay is also very cost-effective, in that the two Rluc fragments can be reproducibly 
produced. Considering the previous methods require costly labels, costly solid-supports, 
as well as costly instrumentation, this method is very advantageous compared to previous 
methods. 
The fluorophore/quencher-based method also has the drawback of low sensitivity 
compared to the previous methods; however, this method is very rapid, taking only 30 
minutes to detect target. This method is superior to the electrochemical and optical 
methods in that detection of multiple targets can be performed in a single well.  
 
6.3 Concluding Remarks 
The methods developed in this dissertation all have the ability to be applied to 
miRNA diagnostics. Therefore, it would be beneficial to further develop these methods in 
order to discover their full diagnostic potential. Due to the heightened understanding of 
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miRNA expression levels, and their implications in disease progression, it would be 
beneficial to the medical world to have diagnostic devices with technological components 
allowing for miRNA quantitation. Already, miRNA expression levels are capable of 
successfully identifying tumor types in cancer patients. It is possible that one day, 
miRNA expression levels may be able to diagnose cancer in the early stages of 
development. Therefore, it is highly important that scientists continue to pursue methods 
for miRNA detection which are capable of translating into the clinical setting. Perhaps in 
the future, the component technologies developed in this dissertation may be applied to 
clinical diagnostic screening devices. 
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Appendix A 
The gene sequence of Rluc cloned into pRSetB is shown in this section. In order 
to clone the Rluc gene into pRSetB, BamHI and EcoRI restriction sites were employed 
based on the pRSetB plasmid sequence. The Rluc gene was amplified by PCR via 
primers that added a BamHI site through the forward primer, and an EcoRI site through 
the reverse primer (See chapter 2, section 2 for details). The N-terminal histidine tag is 
highlighted in green, the BamHI site in yellow, the added base to correct for the reading 
frame in red, and the Rluc gene in grey. A T-7 promoter-specific forward primer was 
employed for the sequencing, which was performed by an Applied Biosystems 3100 
Genetic Analyzer. The EcoRI site cannot be seen from the sequence below due to 
limitations in detectable sequence length. Sequencing employing a T-7 reverse priming 
site reveals the presence of the EcoRI site (data not shown).  
5’ANGGTTTCCTCTGAATATTTTGTTTACTTTAAGAAGGAGATATACATATGCG
GGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGC
AAATGGGTCGGGATCTGTACGACGATGACGATAAGGATCCGATGGCTTCCAA
GGTGTACGACCCCGAGCAACGCAAACGCATGATCACTGGGCCTCAGTGGTGG
GCTCGCTGCAAGCAAATGAACGTGCTGGACTCCTTCATCAACTACTATGATTC
CGAGAAGCACGCCGAGAACGCCGTGATTTTTCTGCATGGTAACGCTGCCTCC
AGCTACCTGTGGAGGCACGTCGTGCCTCACATCGAGCCCGTGGCTAGATGCA
TCATCCCTGATCTGATCGGAATGGGTAAGTCCGGCAAGAGCGGGAATGGCTC
ATATCGCCTCCTGGATCACTACAAGTACCTCACCGCTTGGTTCGAGCTGCTGA
ACCTTCCAAAGAAAATCANGTNNGTGGGCCACNACTGGGGGGCTTGTCTGGC
CTTTCACTACTCCTACNAGCACCAAGACAAGATCCAGGCCATCGTCCATGCT
GAGAGTGTCGTGGACNTGATCGAGTCCTGGGACGAGTGGCCTGACATCNAGG
AGGATATCGCCCTGATCAANAGCGAAAAGGGCNAGAAAATGGTGCTTGAGA 
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Appendix B 
The gene sequence of Rluc + 6x histidine tag are found in this section. The native 
phRL-CMV plasmid containing the Rluc gene does not have a histidine tag for 
purification purposes; therefore, site-directed mutagenesis was performed in order to 
introduce the histidine tag at the N-terminus of the Rluc protein, as well as add an EcoRI 
site for genetic engineering purposes. The histidine tag is highlighted in red, the EcoRI 
site in green, and the Rluc sequence in grey. There are only four codons for the histidine 
tag present, which is due to the fact that the histidine tag sequence is too close in 
proximity to the primer annealing site. An Rluc-specific forward primer was employed 
for the sequencing, which was performed by an Applied Biosystems 3100 Genetic 
Analyzer. 
5’TGCTNCCATCACCATCACGAATTCGCTTCCAGGTGTACGACCCCGAGCAAC
GCAAACGCATGATCACTGGGCCTCAGTGGTGGGCTCGCTGCAAGCAAATGAA
CGTGCTGGACTCCTTCATCAACTACTATGATTCCGAGAAGCACGCCGAGAAC
GCCGTGATTTTTCTGCATGGTAACGCTGCCTCCAGCTACCTGTGGAGGCACGT
CGTGCCTCACATCGAGCCCGTGGCTAGATGCATCATCCCTGATCTGATCGGA
ATGGGTAAGTCCGGCAAGAGCGGGAATGGCTCATATCGCCTCCTGGATCACT
ACAAGTACCTCACCGCTTGGTTCGAGCTGCTGAACCTTCCAAAGAAAATCAT
CTTTGTGGGCCACGACTGGGGGGCTTGTCTGGCCTTTCACTACTCCTACGAGC
ACCAAGACAAGATCAAGGCCATCGTCCATGCTGAGAGTGTCGTGGACGTGAT
CGAGTCCTGGGACGAGTGGCCTGACATCGAGGAGGATATCGCCCTGATCAAG
AGCGAAGAGGGCGAGAAAATGGTGCTTGAGAATAACTTCTTCGTCGAGACCA
TGCTCCCAAGCAAGATCATGCGGAAACTGGAGCCTGAGGAGTTCGCTGCCTA
CCTGGAGCCATTCAAGGAGAAGGGCGAGGTTAGACGGCCTACCCTCTCCTGG
CCTCGCGAGATCCCTCTCGTTAAGGGAGGCAAGCCCGACGTCGTCCAGATTG
TCCGCAACTACAACGCCTACCTTCGGGCCAGCGACGATCTGCCTAAGA-3’ 




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Appendix C 
The Rluc His Tag template plasmid sequence for the engineering of the Rluc split 
plasmids has been reported in Appendix B. The following information in this section 
relates to the genetic engineering of the split Renilla luciferase fragments. The gene 
sequence of the N-terminal fragment, identified as Big Lux, is seen in the following 
sequence data, where the highlighted red sequence represents the first four residues of the 
6x histidine tag (The first two histidine tag codons are present; however, the sequencer 
was not able to detect the adenine bases due to close proximity to the annealing primer), 
the green highlighted sequence represents the EcoRI restriction enzyme site, the blue 
highlighted sequence represents the N-terminal Rluc, and the gold highlighted sequence 
represents the flexible linker, cysteine residues, and stop codons. A T7 promoter-specific 
forward primer was employed. 
5’CNTGCTCCCATCACCATCACGAATTCGCTTCCAGGTGTACGACCCCGAGCA
ACGCAAACGCATGATCACTGGGCCTCAGTGGTGGGCTCGCTGCAAGCAAATG
AACGTGCTGGACTCCTTCATCAACTACTATGATTCCGAGAAGCACGCCGAGA
ACGCCGTGATTTTTCTGCATGGTAACGCTGCCTCCAGCTACCTGTGGAGGCAC
GTCGTGCCTCACATCGAGCCCGTGGCTAGATGCATCATCCCTGATCTGATCGG
AATGGGTAAGTCCGGCAAGAGCGGGAATGGCTCATATCGCCTCCTGGATCAC
TACAAGTACCTCACCGCTTGGTTCGAGCTGCTGAACCTTCCAAAGAAAATCAT
CTTTGTGGGCCACGACTGGGGGGCTTGTCTGGCCTTTCACTACTCCTACGAGC
ACCAAGACAAGATCAAGGCCATCGTCCATGCTGAGAGTGTCGTGGACGTGAT
CGAGTCCTGGGACGAGTGGCCTGACATCGAGGAGGATATCGCCCTGATCAAG
AGCGAAGAGGGCGAGAAAATGGTGCTTGAGAATAACTTCTTCGTCGAGACCA
TGCTCCCAAGCAAGATCATGCGGAAACTGGAGCCTGAGGAGTTCGCTGCCTA
CCTGGAGCCATTCAAGGAGAAGGGCGAGGTTAGACGGCCTACCCTCTCCTGG
CCTCGCGAGATCCCTCTCGTTAAGGGAGGCAGTGGAGGTGGAGGTAGTTGTT
AGTAAAAGCCCGACGTCGTCCAGATTGTCCGCAACTACANCGCCTACCTTCG
GGCCAGCGACGATCTGCCTAAGATGTTCATCGAGTCCGACCCTGGGTTCTTTT
CCAACGCTATTGTCGAGGGAGCTAANAAGTTCCNTAACACCGAGTTCGTGAA
GGTGAAGGCCTCCCTTCACCAGGAGGACCCTCCANATGAAATGGGTAAGTAC
ATCAANAGCTTCNTGGANCGCGTGCTGAAAACGANCAGTATTCTAAGCGNCC
CT-3’ 
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The C-terminal fragment sequencing result after digestion with EcoRI to remove the N-
terminal gene sequence, followed by ligation, is seen in the following sequencing data. 
The red highlighted sequence represents the histidine tag. The green highlighted sequence 
represents the EcoRI site. The gold highlighted sequence represents the flexible linker 
and cysteine residue. The grey highlighted sequence represents the C-terminal Rluc 
fragment (Small Lux). The stop codon is highlighted in purple. The remaining sequence 
represents the phRL-CMV non-coding DNA. The same T7 promotor-specific forward 
primer was used as with the Big Lux. 
5’CNTGCTCCCATCACCATCACGAATTCTGTAGTGGAGGTGGAGGTAGTAAGC
CCGACGTCGTCCAGATTGTCCGCAACTACAACGCCTACCTTCGGGCCAGCGA  
CGATCTGCCTAAGATGTTCATCGAGTCCGACCCTGGGTTCTTTTCCAACGCTA
TTGTCGAGGGAGCTAAGAAGTTCCCTAACACCGAGTTCGTGAAGGTGAAGGG
CCTCCACTTCAGCCAGGAGGACGCTCCAGATGAAATGGGTAAGTACATCAAG
AGCTTCGTGGAGCGCGTGCTGAAGAACGAGCAGTAATTCTAGAGCGGCCGCT
TCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGA
ATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATT
TGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCAT
TTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAA
ACCTCTACAAATGTGGTAAAATCGATAAGGATCCAGGTGGCACTTTTCGGGG
AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGT
ATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAG
GAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGG
CATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAA-3’ 
 
The purified Rluc split fragments are shown in the 12% SDS-PAGE gel photo (Figure 
A.1). Lanes 1 and 4 contain EZ-run protein marker. Lanes 2 and 3 contain purified N-
terminal fragment and C-terminal fragment, respectively. The predicted molecular weight 
of the N-terminal fragment is 31 kDa, while the C-terminal fragment’s predicted 
molecular weight is 15 kDa. 
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Figure A.1 SDS-PAGE gel picture of split Rluc fragment purification. Lane 1-EZ-run protein 
marker. Lane 2-N-terminal Rluc. Lane 3-C-terminal Rluc. Lane 4-EZ-run protein marker. 
Reprinted with permission from Reference 90. Copyright 2009 American Chemical Society. 
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